VICP Registry Case Source Bundle
Canonical URL: https://vicp-registry.org/case/USCOURTS-cofc-1_15-vv-01470
Package ID: USCOURTS-cofc-1_15-vv-01470
Petitioner: B.F.
Filed: 2015-12-04
Decided: 2020-01-14
Vaccine: DTaP
Vaccination date: 2014-03-12
Condition: complex febrile seizures and epilepsy
Outcome: entitlement_granted_pending_damages
Award amount USD: 

AI-assisted case summary:
On December 4, 2015, Andrea Fuller, on behalf of her minor child B.F., filed a petition under the National Vaccine Injury Compensation Program. Petitioner alleged that a DTaP vaccine administered on March 12, 2014, caused B.F. to suffer complex febrile seizures and develop epilepsy. Petitioner further alleged that an MMR vaccine received on September 18, 2014, significantly aggravated B.F.'s condition. B.F. was approximately nine months old at the time of the first vaccination. The respondent argued against compensation, stating the case was not appropriate under the Act. The petitioner presented expert testimony from Dr. Marcel Kinsbourne, who opined that the DTaP vaccine triggered B.F.'s initial seizure through pro-inflammatory cytokine release and that the seizure itself contributed to the development of epilepsy, following the principle that 'seizures beget seizures.' Dr. Kinsbourne also argued the MMR vaccine aggravated the condition. The respondent presented expert testimony from Dr. Gregory Holmes and Dr. Hayley Gans, who argued that B.F.'s RSV infection was the more likely cause of the initial seizure and that there was no evidence linking the vaccines to epilepsy or aggravation. The Special Master, Nora Beth Dorsey, found that the petitioner provided preponderant evidence that the DTaP vaccine administered on March 12, 2014, was a substantial factor in causing B.F.'s complex febrile seizures and epilepsy, satisfying the Althen prongs for causation. The Special Master determined that B.F.'s first seizure on March 15, 2014, three days after vaccination, was a complex febrile seizure, and that this seizure contributed to the development of epilepsy. Entitlement to compensation was granted, with damages to be determined in a separate order. Petitioner was represented by Curtis R. Webb, and respondent was represented by Adriana R. Teitel.

Theory of causation field:
Petitioner Andrea Fuller, on behalf of minor B.F., alleged that a DTaP vaccine administered on March 12, 2014, caused complex febrile seizures and epilepsy, and that an MMR vaccine on September 18, 2014, aggravated the condition. Petitioner's expert, Dr. Marcel Kinsbourne, opined that the DTaP vaccine triggered the initial seizure via pro-inflammatory cytokine release, and that this seizure led to epilepsy ('seizures beget seizures'). He also argued the MMR vaccine aggravated the condition. Respondent's experts, Dr. Gregory Holmes and Dr. Hayley Gans, contended that B.F.'s RSV infection was the more likely cause of the initial seizure, and that vaccines were not linked to epilepsy or aggravation. The Special Master, Nora Beth Dorsey, found that the DTaP vaccine was a substantial factor in causing B.F.'s complex febrile seizures and epilepsy, satisfying the Althen prongs. The first seizure on March 15, 2014 (three days post-vaccination) was deemed complex and contributing to epilepsy. Entitlement was granted. Petitioner's counsel was Curtis R. Webb; respondent's counsel was Adriana R. Teitel. Decision Date: January 14, 2020.

Public staged source text:

================================================================================
DOCUMENT 1: USCOURTS-cofc-1_15-vv-01470-2
Date issued/filed: 2020-01-14
Pages: 24
Docket text: PUBLIC RULING (Originally filed: 12/17/2019) regarding 140 Ruling on Entitlement. Signed by Special Master Nora Beth Dorsey. (mca) Service on parties made.
--------------------------------------------------------------------------------
Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 1 of 24
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
Filed: December 17, 2019
* * * * * * * * * * * * * * *
ANDREA FULLER, on behalf of her * PUBLISHED
Minor Child, B.F., *
*
Petitioner, * No. 15-1470V
*
v. * Special Master Nora Beth Dorsey
*
SECRETARY OF HEALTH * Entitlement; Diphtheria-Tetanus-Acellular-
AND HUMAN SERVICES, * Pertussis (DTaP) Vaccine; Measles Mumps
* Rubella (MMR) Vaccine; Febrile Seizures;
Respondent. * Epilepsy.
*
* * * * * * * * * * * * * * *
Curtis R. Webb, Twin Falls, ID, for petitioner.
Adriana R. Teitel, U.S. Department of Justice, Washington, DC, for respondent.
RULING ON ENTITLEMENT1
I. INTRODUCTION
On December 4, 2015, Andrea Fuller (“petitioner”), on behalf of her minor child, B.F.,
filed a petition under the National Vaccine Injury Compensation Program (“Vaccine Act” or “the
Program”), 42 U.S.C. § 300aa-10 et seq. (2012).2 Petitioner alleges that as a result of receiving a
diphtheria-tetanus-acellular-pertussis (“DTaP”) vaccine on March 12, 2014, B.F. suffered from
complex febrile seizures and developed epilepsy, and a measles mumps rubella (“MMR”)
1 Because this Ruling contains a reasoned explanation for the action in this case, the undersigned
is required to post it on the United States Court of Federal Claims’ website in accordance with
the E-Government Act of 2002. 44 U.S.C. § 3501 note (2012) (Federal Management and
Promotion of Electronic Government Services). This means the Ruling will be available to
anyone with access to the Internet. In accordance with Vaccine Rule 18(b), petitioner has 14
days to identify and move to redact medical or other information, the disclosure of which would
constitute an unwarranted invasion of privacy. If, upon review, the undersigned agrees that the
identified material fits within this definition, the undersigned will redact such material from
public access.
2 The National Vaccine Injury Compensation Program is set forth in Part 2 of the National
Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755, codified as amended,
42 U.S.C. §§ 300aa-10 to -34 (2012). All citations in this decision to individual sections of the
Vaccine Act are to 42 U.S.C. § 300aa.

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 2 of 24
vaccine B.F. received on September 18, 2014 significantly aggravated B.F.’s condition.
Amended Petition (“Am. Petition”) at 2 (ECF No. 132). Respondent argued against
compensation, stating that “this case is not appropriate for compensation under the terms of the
Act.” Respondent’s Report (“Resp. Rept.”) at 2 (ECF No. 15).
After carefully analyzing and weighing the evidence presented in this case in accordance
with the applicable legal standards, the undersigned finds that petitioner provided preponderant
evidence that the DTaP vaccine B.F. received on March 12, 2014 caused her to develop complex
febrile seizures and epilepsy, which satisfies her burden of proof under Althen v. Sec’y of Health
and Human Servs., 418 F.3d 1274, 1280 (Fed. Cir. 2005). Accordingly, petitioner is entitled to
compensation.
II. BACKGROUND
A. Procedural History
Petitioner filed her claim on December 4, 2015, and she filed various medical records on
January 12, 2016. See Petitioner’s Exhibits (“Pet. Exs.”) 1-13. She also filed a Statement of
Completion with the medical records. (ECF No. 10). On April 22, 2016, respondent filed a Rule
4(c) Report, in which he recommended against compensation. Resp. Rept. at 2. Emphasizing
that “temporal proximity alone is insufficient to establish specific causation,” respondent
maintained that petitioner failed to provide a reputable scientific theory that supports the claim
that B.F. experienced seizures as a result of the DTaP vaccination she received and failed to
address why the vaccination was more likely than not the cause of B.F.’s condition. Id. at 13.
Respondent also stated that petitioner had yet to provide an expert report in support of her claim.
Id.
On July 21, 2016, the undersigned granted the petitioner’s motion to substitute counsel
from Andrew Downing to Curtis Webb. Order dated July 21, 2016 (ECF No. 26). A status
conference was held with Mr. Webb on August 16, 2016. Petitioner subsequently filed updated
medical records on October 17, 2016. Pet. Exs. 14-20. Petitioner then filed an expert report
from Dr. Marcel Kinsbourne on November 30, 2016, as well as several articles referenced in Dr.
Kinsbourne’s report on December 6, 2016. Pet. Exs. 21-32. Respondent filed responsive expert
reports from Dr. Gregory Holmes and Dr. Hayley Gans on May 19, 2017, along with related
medical literature on October 19, 2017. Respondent’s Exhibits (“Resp. Exs.”) A-D. Dr.
Kinsbourne filed a supplemental expert report with supporting medical literature on November
13, 2017. Pet. Exs. 33-47.
During a status conference on January 30, 2018, the undersigned provided the parties
with her preliminary opinions in the case. Rule 5 Order dated Jan. 31, 2018 (ECF No. 72). She
stated that she found two positions set forth in petitioner’s expert report compelling: that the
vaccine was a substantial factor in triggering the onset of seizures, and that the subsequent MMR
vaccine was a significant aggravation of B.F.’s. condition. Id. at 1. She encouraged the parties
to consider settlement, but when the parties did not reach an agreement, she instead scheduled an
entitlement hearing for October 16-18, 2018. Order dated Mar. 5, 2018 (ECF No. 78). In
response to Dr. Kinsbourne’s second report, respondent filed a supplemental report from Dr.
2

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 3 of 24
Holmes on April 6, 2018. Resp. Ex. E. Respondent also filed a supplemental report from Dr.
Gans on April 10, 2018. Resp. Ex. F. On July 2, 2018, petitioner filed Dr. Kinsbourne’s
responses to the supplemental reports of Dr. Holmes and Dr. Gans. Pet. Exs. 51-52. Respondent
filed second supplemental reports from Dr. Holmes and Dr. Gans on October 1, 2018. Resp.
Exs. G-H.
Prior to the scheduled entitlement hearing, pre-hearing submissions were filed by
petitioner on August 31, 2018 (ECF No. 99), and by respondent on October 1, 2018 (ECF No.
106). The parties then filed their joint prehearing submission on October 3, 2018. (ECF No.
108). During the hearing on October 16-17, 2018, petitioner, Dr. Kinsbourne, Dr. Holmes, and
Dr. Gans each testified. Transcript (“Tr.”) 3. Following the hearing, petitioner filed a post-
hearing brief on January 2, 2019. (ECF No. 116). Petitioner also filed B.F.’s updated medical
records and her school records on January 15, 2019, as requested during the hearing. Pet. Exs.
69-74. Respondent subsequently filed a post-hearing brief on May 3, 2019. (ECF No. 123).
Petitioner then filed a reply brief on June 13, 2019, as well as an amended petition on July 3,
2019. (ECF Nos. 128, 132).
This matter is now ripe for adjudication.
B. Summary of Relevant Facts3
B.F. was born at thirty-five weeks on May 31, 2013, with no noted complications. Pet.
Ex. 68 at 2. She was seen by her pediatrician, Dr. Robert Parkey, for routine well baby checks
on June 3, June 14, July 1, and August 1, 2013. Pet. Ex. 3 at 43-55. At her four-month well
check on November 13, 2013, Dr. Parkey noted that B.F. had good growth and development for
her age. Id. at 62-64. She received Prevnar, rotavirus, Hib, DTaP, and IPV vaccinations at this
visit. Id. at 64.
Petitioner took B.F. to the pediatrician on February 18, 2014, with complaints of eye
irritation and drainage, cough, fever, and a runny nose for ten days. Pet. Ex. 3 at 67. She was
diagnosed with an ear infection and conjunctivitis and prescribed an antibiotic. Id. at 69. B.F.
had her nine-month well check on March 12, 2014. Id. at 71-73. Dr. Parkey noted that she was
doing well developmentally and an examination of her nose, throat, ears, and chest was normal.
Id. at 71-72. She received her third set of vaccinations during this visit, including DTaP, Hib,
IPV, Hepatitis B, and Prevnar. Id. at 73.
On March 15, 2014, B.F. had a generalized febrile seizure while at a restaurant with her
family. Pet. Ex. 3 at 74. This was her first seizure and she was subsequently seen in the St.
Joseph’s Regional Medical Center Emergency Room. Id. B.F.’s records from the emergency
room indicate that her seizure “lasted for about ten minutes.” Id. B.F. was described as being
3 The parties set forth a Stipulation of Facts in their Joint Prehearing Submission. See Joint
Prehr’g Submission, filed Oct. 3, 2018 (ECF No. 108). Most of the stipulated facts have been
incorporated into this summary. The undersigned notes that “[a]lthough the parties agree on
most of the facts relevant to the [p]etitioner’s claim, they disagree on the medical and legal
significance of those facts.” Id. at 7.
3

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 4 of 24
postictal. Id. According to her mother, B.F.’s seizure activity “lasted between 10-15 minutes.”
Pet. Ex. 67 at 2. At the hospital, B.F. had a rectal temperature of 100.2°F, and it was noted that
she had about a month of nasal congestion that had increased over the past few days, along with
a cough. Pet. Ex. 3 at 74. A CAT scan was normal, but a chest x-ray showed evidence of
bronchiolitis and a swab taken to test for respiratory syncytial virus (“RSV”) was positive. Id. at
74, 76.
B.F. had a second febrile seizure on April 29, 2014, at 2:00 a.m., while she was sleeping.
Pet. Ex. 3 at 108; Pet Ex. 67 at 3. Her parents heard gagging sounds and found her seizing in
bed. Pet. Ex. 3 at 108. B.F. had a temperature of 100.5°F. Id. The total duration of the seizure
is unknown, but the observed portion was five minutes and generalized. Id. Later that day, B.F.
was seen by Dr. Parkey for upper respiratory symptoms including fever, runny nose, and a six-
day history of vomiting. Id. at 96. Petitioner informed Dr. Parkey of the seizure that occurred
during the night. Id.
B.F. had a third seizure while being bathed on April 30, 2014, and was again taken to the
St. Joseph’s Regional Medical Center ER, where she was noted to have a fever of 102.7°F. Pet.
Ex. 3 at 88; Pet. Ex. 67 at 3. The seizure lasted for approximately thirty minutes in total,
beginning fifteen minutes before she arrived at the hospital and continuing for fifteen to twenty
minutes in the ER. Pet. Ex. 3 at 88-89. Her seizure stopped after administration of rectal
Valium. Id. at 89. B.F. was admitted overnight for observation and an initial EEG study, and
she was prescribed Tegretol for seizures. Id. at 115-16. The EEG performed on May 1 was
interpreted by Dr. Arif Chowdhury, who described the result as an “[a]bnormal EEG recording
due to asymmetry in the right frontotemporal area with sharp contouring activity suggestive of
possible seizure.” Id. at 100. B.F. was diagnosed with prolonged febrile seizures. Id. at 89. In
the hospital discharge note on May 1, 2014, Dr. Parkey wrote that B.F. was admitted after
“prolonged, presumptive atypical febrile seizure. . . . [She] had a similar prolonged initial febrile
seizure on 03/15/2014.” Id. at 115.
On May 2, 2014, B.F. was seen for follow-up by Dr. Parkey, who noted that B.F.’s first
seizure “[w]as > 10 minutes in duration.” Pet. Ex. 3 at 101-02. B.F.’s diagnosis was recurrent
seizures. Id. at 103. Dr. Parkey ordered an MRI and neurology referral. Id. Dr. Parkey noted
that “seizures seem atypical and are concerning for more than just simple febrile seizures.” Pet.
Ex. 3 at 104. After her most recent seizure, B.F. was described as tired and a little unsteady. Id.
B.F. was seen by neurologist Dr. Gregory MacDonald on May 6, 2014. Pet. Ex. 3 at 107.
Dr. MacDonald wrote, “[B.F.] has had one, and possibly 2, complex (prolonged) febrile seizures.
. . . She has a 40% risk of another febrile seizure after each one - complexity of prior one raises
the risk that another one might be complex (prolonged, focal, or recurrent within 24 hours).” Id.
The results of the MRI were “essentially normal.” Id. Dr. MacDonald’s record indicates that
B.F.’s lifetime risk of epilepsy was low at 7%. Id. He stopped Tegretol and recommended that
B.F. use Diastat as needed for prolonged or repetitive seizures. Id.
On May 11, 2014, B.F. had a forty-minute seizure that required three doses of Valium to
be administered. Pet. Ex. 3 at 117-18. Her temperature was 100.8°F when the seizure began.
Id. at 117. B.F. had a chest x-ray and was diagnosed with early pneumonia by the ER physician.
4

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 5 of 24
Id. at 118. The next day, petitioner took B.F. to see Dr. Parkey for a follow-up. Id. at 125.
Petitioner stated that this seizure was different than previous ones because B.F. “seemed to know
it was going to happen.” Id. Because the seizure was very long and there did not appear to be a
fever associated with it, Dr. Parkey concluded that it was reasonable to start AED therapy (an
anti-epileptic drug) and prescribed Keppra. Id. at 128. B.F. was diagnosed with a seizure
disorder. Id. at 127.
On June 5, 2014, petitioner sought a second opinion at Seattle Children’s Hospital. Pet.
Ex. 3 at 139-40. B.F. was seen in the hospital’s Neurology Clinic and an EEG was performed.
Id. The EEG showed “[n]o epileptiform discharges.” Id. at 139. Dr. John Kurantani, the
interpreting physician, noted that “[t]his EEG does not rule out diagnosis of epilepsy,” and
recommended clinical correlation. Id. After evaluating B.F., Drs. Michah Brasseur and James
Owens concluded that “[i]t would not be unreasonable to continue to treat [her] with Keppra for
short-term,” but that Keppra would likely not prevent her from having additional febrile seizures.
Id. at 143-44.
B.F. had another seizure accompanied by a fever on June 29, 2014, that lasted fifty
minutes. Pet. Ex. 3 at 153; Pet. Ex. 11 at 24. She was taken to the ER and given two doses of
Diastat to stop the seizure. Pet. Ex. 11 at 24. She was prescribed an antibiotic for her fever and
cough and discharged from the hospital. Id. at 24-25. After this seizure, B.F was seizure free for
almost three months, from June 29, 2014 to September 25, 2014.
At B.F.’s fifteen-month well check on September 18, 2014, Dr. Parkey noted that B.F.
was doing well with an increased dose of Keppra and that her development and growth were
normal. Pet. Ex. 3 at 154, 157. During this visit, B.F. received her fourth Hib and Prevnar
vaccinations and her first MMR vaccination. Id. at 156. On September 25, 2014, petitioner
called Dr. Parkey’s office to inform him that B.F. had a febrile seizure that morning. Id. at 158.
Petitioner had to administer two doses of Diastat to stop the seizure.4 Id. About two months
after, on November 23, 2014, B.F. was seen in the ER after having another seizure at home. Id.
at 162. In the ER, her temperature was 101°F and her parents reported that she had a “croupy
cough.” Id. Her chest x-ray showed bronchiolitis and interstitial pneumonitis; she was
prescribed an antibiotic for pneumonia and discharged. Id. at 162-64.
B.F. had her eighteen-month well check with Dr. Parkey on December 11, 2014. Pet. Ex.
3 at 166. Dr. Parkey noted that B.F. had approximately seven seizures over the past three
months which “typically start[ed] with a ‘scream’, gurgling noise, facial twitching, eye deviation,
some ext twitching.” Id. Otherwise, B.F. demonstrated good growth and development for her
age. Id. Petitioner was instructed to increase B.F.’s dose of Keppra and return for a two-year
well check. Id. at 169.
4 B.F.’s “parents had been instructed to administer [Diastat] if a seizure lasted more than five
minutes, and to administer a second dose [] if the first dose did not stop the seizure. [B.F.’s]
September 25, 2014 seizure did not stop until [her] mother had given her two doses of [Diastat].”
Joint Prehr’g Submission at ¶ 42 (citing Pet. Ex. 14 at 54).
5

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 6 of 24
B.F. was seen by her neurologist, Dr. MacDonald, on March 31, 2015. Pet. Ex. 3 at 189.
He noted that B.F. had 25 or more seizures in the past year, including some while taking Keppra
and some that occurred in the absence of a fever or illness. Id. at 190. Dr. MacDonald
diagnosed her with unspecified epilepsy. Id. at 189. Because B.F. was still having seizures on
Keppra and experiencing side effects, Dr. MacDonald and petitioner decided to start B.F. on
Zonegran in addition to Keppra. Id.
Between April and July 2015, petitioner called Dr. MacDonald’s office several times to
notify him that B.F. was having breakthrough seizures and more frequent seizures in general.
See generally Pet. Ex. 5 at 93-113. B.F.’s medications were changed and adjusted periodically
during this time. Id.
B.F. was seizure free for 127 days, until February 1, 2016, when petitioner called Dr.
MacDonald’s office to report that B.F. had two febrile seizures within twenty-four hours. Pet.
Ex. 19 at 14. B.F. had her annual follow-up appointment with Dr. MacDonald shortly after, on
March 11, 2016. Id. at 23. He reported that her general health was good and her development
was normal. Id. at 24. Dr. MacDonald instructed petitioner that B.F. should remain on Topamax
twice daily to manage her seizures. Id. at 22. Dr. MacDonald’s goal was for B.F. to go at least
one year without seizures, at which point he would consider a trial period without medication.
Id.
B.F. had six seizures between her 2016 annual appointment with Dr. MacDonald and her
2017 annual appointment on March 20, 2017. Pet. Ex. 48 at 31. She had one febrile seizure in
April 2016 but was then seizure free for 256 days until January 2017, when she had five seizures
during the month. Id. All five of the January 2017 seizures were associated with illness and
fever, and none required rescue medication. Id. Dr. MacDonald’s report from the March 20,
2017 visit indicates that B.F. likely has “an idiopathic focal epilepsy, with secondarily
generalized focal seizures with impairment of awareness” that “manifested as clinically
generalized convulsive seizures.” Id. at 29. He also stated that “genetic generalized epilepsy
remains possible and would be more consistent with her breakthroughs with fever. GEFS+
[genetic epilepsy with febrile seizures plus] might be considered, but there is no corroborative
family history.” Id. Dr. MacDonald’s diagnosis was refractory focal epilepsy. Pet. Ex. 48 at 30.
Throughout the summer of 2017, B.F. “had increased unprovoked seizures . . . as often as
twice per week” and was “[i]ncontinent of urine and feces with several of them.” Pet. Ex. 48 at
92. Dr. MacDonald increased her topiramate dosage in response, and as of her November 1,
2017 appointment with Dr. MacDonald, B.F. had been seizure free since the end of September
2017. Id. At the November 1, 2017 appointment, Dr. MacDonald changed B.F.’s medication
from Topamax (topiramate) to Depakote. Id. at 89-90.
In late November 2017, B.F. had a series of seizures associated with an ear infection.
Pet. Ex. 48 at 137. Within the first few weeks of December 2017, she had three seizures lasting
less than five minutes each. Tr. 21-22. She had another seizure in March 2018 in the setting of a
fever and respiratory virus that required petitioner to administer Klonopin. Id. at 22.
6

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 7 of 24
At the time of the hearing, B.F.’s most recent seizure had occurred on June 9, 2018. Pet.
Ex. 70 at 56; Tr. 22. She started kindergarten in the fall of 2018 and was adjusting well to the
traditional classroom setting. Tr. 22-23. Petitioner testified that B.F.’s doctors had not raised
any concerns about developmental or cognitive delays, but there was a 504 Education Plan in
place at B.F.’s school to provide necessary accommodations for her seizure disorder. Tr. 29-30.
As of her December 5, 2018 appointment with her neurologist, B.F. was still taking Depakote to
control seizure activity. Pet. Ex. 70 at 56.
C. Petitioner’s Testimony
During the entitlement hearing, petitioner testified regarding her own experiences and the
course of B.F.’s condition. Petitioner is a registered nurse who currently works as a case
management supervisor. Tr. 6. B.F. was healthy when she received her vaccinations on March
12, 2014 and did not show any symptoms of a cold or other illness. Tr. 7. Petitioner indicated
that B.F. seemed “a little bit tired” the morning before she experienced her first seizure, and on
the day of the seizure, B.F. had “just a little tiny cough . . . , but nothing of alarm.” Id. When
B.F. experienced her first seizure on March 15, 2014, petitioner was feeding B.F. lunch at a
restaurant when petitioner noticed that B.F.’s “eyes kind of fluttered back into the back of her
head, and then she went limp.” Tr. 8. Petitioner’s aunt, who is an EMT and was also at the
restaurant, helped care for B.F. and transport her to the hospital. Id. B.F. was still seizing upon
arrival at the hospital but stopped shortly after she arrived. Id. Petitioner estimated that this first
seizure was “between 10 and 15 minutes” in duration. Tr. 9.
Petitioner stated that B.F had several seizures throughout the spring before she began to
improve in May 2014. Tr. 10. B.F. had another seizure on June 29, 2014, after which she was
prescribed Tegretol, which was later switched to Dilantin. Tr. 14-15. B.F. had a seizure-free
period until September 25, 2014, when petitioner testified that B.F. had a seizure that was “a
little bit more intense,” and required the administration of Diastat to stop seizure activity. Tr. 16-
17. Petitioner described the effect of the Diastat on B.F., stating that it made her “very upset,
very whiny, clingy.” Tr. 17. B.F. received an MMR vaccination one week prior to this seizure,
on September 18, 2014. Tr. 15.
Petitioner testified that B.F. continued to have seizures at varying frequency over the next
few years, with the most recent occurring in June 2018. Tr. 18. With the advice of a speech
therapist, petitioner began to keep a journal of B.F.’s seizures in order to determine potential
causes or stressors. Tr. 20. Petitioner stated that while B.F. has seizures with and without
illness, illness is one of her “major stressors.” Tr. 24-25. B.F. started kindergarten in the fall of
2018 and “is tolerating school well,” but petitioner expressed concerns about the impact of B.F.’s
seizures on her “long-term future” and her ability to “learn as everybody else can.” Tr. 22-23,
26. B.F. is in a mainstream classroom and has a 504 Plan in place with her school, but no
Individualized Education Program (“IEP”) at this time. Tr. 29. Petitioner stated that there are no
concerns about developmental or cognitive delays at this time and Dr. MacDonald has not raised
the issue of genetic testing. Tr. 30.
7

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 8 of 24
D. Febrile Seizures and Epilepsy
Febrile seizures occur in 2-5% of children under the age of five. Resp. Ex. A, Tab 31 at
1.5 A febrile seizure is defined as “a seizure occurring in childhood after one month of age,
associated with a febrile illness that is not caused by an infection of the central nervous system.”
Id. at 2. There are two types of febrile seizures: simple and complex. Id. Most febrile seizures
are simple, and only approximately 20-30% are complex. Id. There is a disagreement between
the parties here as to the definition of a complex febrile seizure, specifically as to the duration of
the seizure, discussed more fully below.
Epilepsy is defined as “two unprovoked seizures.” Tr. 144. Evidence shows “[febrile
seizures] are associated with an increased risk of subsequent epilepsy, and that epilepsy develops
in 2 to 4% of children with a history of [febrile seizures].” Resp. Ex. A, Tab 31 at 7. “[T]he risk
of developing epilepsy can be as great as 57% in children with focal, prolonged, and recurrent
[febrile seizures].” Id. The causes of febrile seizures are multifactorial and include
“inflammation, brain pH, and genetic factors.” Pet. Ex. 28 at 481-82.6
Febrile seizures have a “major genetic predisposition.” Resp. Ex. A, Tab 29 at 2.7 While
multiple genes have been implicated, a “genetic tendency is clearly insufficient in itself to cause
febrile seizures.” Id. Due to the increased risk of long-term consequences attendant to complex
seizures, there has been an effort to distinguish simple from complex febrile seizures. “Complex
febrile seizures are followed by epilepsy in 4-15%” of children, whereas “simple febrile seizures
have a risk of subsequent epilepsy of 2-3%.” Id. at 3.
E. Expert Reports
1. Petitioner – Dr. Marcel Kinsbourne, M.D.
a. Background and Qualifications
Dr. Kinsbourne earned his B.A. from Christ Church at Oxford University. Pet. Ex. 22 at
1. He earned his Bachelor of Medicine (B.M.) and Bachelor of Surgery (B.Ch.) from Oxford
University Medical School. Id. He also earned an M.A. and a Doctor of Medicine (D.M.) from
Oxford University. Id. From 1974 to 1980, he was the Senior Staff Physician at the Hospital for
Sick Children in Toronto, and also the Director of the Behavioral Neurology Unit at Boston
University’s Sargent College of Allied Health Professions from 1973 to 1982. Id. at 2. Dr.
5 Syndi Seinfeld & John M. Pellock, Recent Research on Febrile Seizures: A Review, 4 J.
Neurology & Neurophysiology 1 (2013).
6 Bo Feng & Zhong Chen, Generation of Febrile Seizures and Subsequent Epileptogenesis, 32
Neuroscience Bull. 481 (2016).
7 Peter Camfield & Carol Camfield, Febrile Seizures and Genetic Epilepsy with Febrile Seizures
Plus (GEFS+), 17 Epileptic Disorders 124 (2015).
8

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 9 of 24
Kinsbourne also served as the Director of the Behavioral Neurology Department at the Eunice
Kennedy Shriver Center from 1980 to 1991. Id. Throughout his career, Dr. Kinsbourne has held
teaching positions at various institutions. Id. He is currently a Research Professor at Tufts
University’s Center for Cognitive Studies. Id. Dr. Kinsbourne is licensed to practice medicine
in the United Kingdom, Canada, North Carolina, Massachusetts, and Virginia. Id. at 1. Dr.
Kinsbourne has served and is currently serving on a number of editorial boards, including
Archives of Clinical Neuropsychology and Cognitive Neuropsychiatry. Id. at 3. He has
authored or co-authored more than 400 publications. Id. at 5-39.
b. Opinion
Dr. Kinsbourne explains that vaccines activate the innate immune system by stimulating
the release of pro-inflammatory cytokines, and such release “is a necessary condition for the
genesis of the adaptive immunity which vaccination is intended to engender.” Pet. Ex. 21 at 4.
While pro-inflammatory cytokine release stimulated by a vaccine is almost always “perfectly
normal,” in certain individuals “the flow of cytokines is excessive . . . [and] initiates seizure
activity.” Tr. 35. Here, the vaccines stimulated or overstimulated the innate immune system in a
child with unusual sensitivity, causing seizures. Tr. 35-36. Dr. Kinsbourne alleges that this
cytokine release mechanism was “operative” in B.F.’s case, because “her onset seizure occurred
within seventy-two hours of the vaccinations and it is the innate immune system that can mount
so rapid a response.” Pet. Ex. 21 at 4. Dr. Kinsbourne states that B.F.’s March 15, 2014 seizure
was “within a medically reasonable temporal interval for seizure caused by DTaP,” and thus, the
vaccine was “a substantial factor in triggering the onset seizure, and most likely. . . the sole
cause.” Id. at 3-4.
On cross-examination, Dr. Kinsbourne was questioned whether B.F.’s first seizure
occurred beyond three days of vaccination,8 or outside the recognized time frame for a vaccine-
related seizure associated with the DTaP vaccine. Dr. Kinsbourne testified that the day a vaccine
is administered is considered “day zero.” Tr. 59; see also Resp. Ex. F, Tab 1 at 3 (“The day of
vaccination was defined as day 0.”).9 B.F. received her DTaP vaccine on March 12, 2014, and
had her first seizure on March 15, 2014, “day three” after vaccination. Pet. Ex. 3 at 71-74. Dr.
Kinsbourne cited the Braun et al. study to support his testimony. In Braun, “[o]f the 33 infants
with known interval from vaccination to seizure, 11 (33%) had seizures the same day as
vaccination, and 20 (61%) had seizure[s] 1 to 3 days after vaccination.” Pet. Ex. 36 at 4.10
8 Medical records show that B.F. had her March 12, 2014 vaccinations at approximately 8:30
a.m. and her first seizure occurred at approximately 12:30 p.m. on March 15, 2014. Pet. Ex. 3 at
71; Pet. Ex. 11 at 184.
9 Yuelian Sun et al., Risk of Febrile Seizures and Epilepsy After Vaccination with Diphtheria,
Tetanus, Acellular Pertussis, Inactivated Poliovirus, and Haemophilus Influenzae Type B, 307
JAMA 823 (2012).
10 M. Miles Braun et al., Infant Immunization with Acellular Pertussis Vaccines in the United
States: Assessment of the First Two Years’ Data from the Vaccine Adverse Event Reporting
(. . . continued)
9

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 10 of 24
On re-cross, Dr. Kinsbourne testified that DTaP vaccinations were sufficient to cause
febrile seizures three days after vaccination. Tr. 94. The Institute of Medicine (“IOM”) supports
Dr. Kinsbourne’s position that the temporal association between B.F.’s vaccination and first
seizure is appropriate. The IOM discusses a study by Huang et al.,11 which evaluated the risk of
seizures in 433,654 children who received a total of 1,343,067 doses of DTaP. Pet. Ex. 45 at
540-41.12 In this study, “[t]he exposed person-time period was defined as 0 to 3 days after DTaP
vaccination.” Id. at 540.
Although Dr. Kinsbourne acknowledges that B.F. tested positive for RSV, he argues that
her “[RSV] did not cause any seizure activity” because her RSV infection was “quite
longstanding,” and she had a seizure only after vaccination. Pet. Ex. 21 at 3. There is no doubt,
according to Dr. Kinsbourne, that B.F.’s vaccines contributed to her initial seizure. Tr. 33. Dr.
Kinsbourne agrees that B.F. tested positive for RSV and had upper respiratory symptoms which
were attributable to RSV. Tr. 44. He concedes that RSV could have played a role in the cause
of B.F.’s first seizure but testified that RSV was not the sole cause. Id. Dr. Kinsbourne also
opined that the combined effect of her underlying illness (her RSV infection) and vaccination
caused B.F.’s first seizure. Tr. 81-82. Petitioner filed an article by Le Saux et al., which
supports Dr. Kinsbourne’s opinion as to concurrent viral infections in children with febrile
seizures. In Le Saux, the authors examined the incidence of hospitalization for children with
febrile seizures after receipt of pertussis and MMR vaccines. Pet. Ex. 41 at e348.13 For purposes
of the study, the authors “included children who had concurrent identification of common viral
infections, which may have contributed to the seizure.” Id. at e352.
Dr. Kinsbourne suggests that seizures lasting longer than ten minutes should be classified
as complex, and therefore B.F.’s first seizure on March 15, 2014, which lasted at least ten
minutes, is classifiable as a complex febrile seizure. Tr. 33; Pet. Ex. 21 at 4. Dr. Kinsbourne
identified three reasons to support his opinion that B.F.’s first seizure was a complex febrile
seizure. First, citing data in Hesdorffer et al., the median duration of a first seizure was
approximately four minutes, and B.F.’s was certainly longer. Pet. Ex. 39 at 4.14 Second, B.F.’s
System (VAERS), 106 Pediatrics 1 (2000).
11 Wan-Ting Huang et al., Lack of Association Between Acellular Pertussis Vaccine and
Seizures in Early Childhood, 126 Pediatrics e263 (2010). Respondent filed this study as
Respondent’s Exhibit F, Tab 2.
12 Comm. to Review Adverse Effects of Vaccines, Inst. of Med., Adverse Effects of Vaccines:
Evidence and Causality (Kathleen Stratton et al. eds., 2011).
13 Nicole Le Saux et al., Decrease in Hospital Admissions for Febrile Seizures and Reports of
Hypotonic-Hyporesponsive Episodes Presenting to Hospital Emergency Departments Since
Switching to Acellular Pertussis Vaccine in Canada: A Report from IMPACT, 112 Pediatrics
e348 (2003).
14 Dale C. Hesdorffer et al., Distribution of Febrile Seizure Duration and Associations with
(. . . continued)
10

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 11 of 24
treating physicians described her initial seizure as atypical, and later described it as complex.
Pet. Ex. 3 at 75, 97, 107. Third, in studies, prolonged febrile seizures have been defined as
lasting ten minutes. See, e.g., Pet. Ex. 39 at 6; Resp. Ex. E, Tab 5 at 1-2.15
Dr. Kinsbourne cites the Hesdorffer article to support his position that a seizure lasting
ten minutes should be classified as complex. Hesdorffer studied the duration of first febrile
seizures in 158 children. The median duration of first febrile seizures was approximately four
minutes. Pet. Ex. 39 at 4. Using this data, the researchers determined cut off times for simple
and complex febrile seizures by identifying a group with short first febrile seizures, and another
with prolonged first febrile seizures. The data supported a definition of using ten minutes as the
upper limit for simple febrile seizures. Id. at 6. They applied a more data driven approach,
which Dr. Kinsbourne asserts should override the older clinical approach. Tr. 93. Trinka et al.
also supports Dr. Kinsbourne’s position as to seizure duration. The authors in Trinka state,
“[o]bservations from a [] pediatric population show . . . two subgroups [], one with . . . brief
seizures (<5 min) and the other . . . more prolonged seizures. In this study, a seizure that lasted
>7 min was likely to be prolonged.” Resp. Ex. A, Tab 21 at 3.16
According to Dr. Kinsbourne, a complex febrile seizure contributes to the probability of
epilepsy. Tr. 39. He opines that B.F.’s March 15, 2014 seizure likely contributed to B.F.’s
epilepsy because “[c]omplex febrile seizures have a much more significant risk of being
followed by more febrile seizures and then afebrile seizures, meeting the definition of epilepsy.”
Tr. 38-39. The adage that “seizures beget seizures” still holds true in a subset of children,
“whose first seizure causes changes in the brain, making neurons hyperexcitable and more prone
to generate seizures than is normal.” Tr. 40-41. Dr. Kinsbourne explained the mechanism
underlying this process as follows. Vaccination triggers the release of chemicals (cytokines),
which signal the brain to generate fever. Tr. 43. Neurons and glial cells emit more cytokines
which cause inflammatory changes. Id. Inflammatory changes “can have the effect of
permanently raising the level of excitability of neurons, particularly in the hippocampus, which
is the main risk area for seizure generation.” Id. Moreover, Dr. Kinsbourne opined that there is
a cumulative effect each time a seizure occurs. Id.
Dr. Kinsbourne cites the Feng and Chen article in support of his theory. Inflammation,
specifically the release of pro-inflammatory cytokines during fever, are thought to trigger febrile
seizures. “[F]ever induces the production and release of [the cytokine] IL-1β, which
subsequently triggers seizures. Seizures occur when the balance of neuronal excitation and
inhibition is altered by neuronal inflammation.” Pet. Ex. 28 at 482. “In turn, the seizure itself
leads to inflammatory responses. Evidence from clinical observations and experiments shows
that IL-1β contributes not only to the generation of [febrile seizures], but also to the
epileptogenesis thereafter.” Id. Thus, as Feng and Chen determined, the cytokine “IL-1β is a
Development, 70 Annals Neurology 1 (2011).
15 Anne T. Berg & Shlomo Shinnar, Complex Febrile Seizures, 37 Epilepsia 126 (1996).
16 Eugen Trinka et al., A Definition and Classification of Status Epilepticus – Report of the ILAE
Task Force on Classification of Status Epilepticus, 56 Epilepsia 1515 (2015).
11

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 12 of 24
substantial factor in the initiation of seizures and it also plays a role in the aftermath of prolonged
[febrile seizures].” Id.
Dr. Kinsbourne also cites notes by Dr. MacDonald, B.F.’s treating neurologist, in support
of his theory. Dr. MacDonald wrote that “each complex seizure makes it more likely that one
has another such seizure.” Tr. 43-44 (citing Pet. Ex. 16 at 4). Dr. Kinsbourne believes that a
complex seizure can change the course of a child’s seizure disorder and increase the risk of
epilepsy. Dr. Kinsbourne cites a number of articles in support of his theory of causation.
Vezzani et al. explains that “[s]eizures, the hallmarks of epilepsy, originate from synchronized
aberrant firing of neuronal populations due to underlying hyperexcitability phenomena.” Pet.
Ex. 32 at 1281.17 Clinical and experimental studies suggest that proinflammatory cytokines
“contribute to aberrant neuronal excitability underlying seizures.” Id. In animal studies,
transient inflammation caused by seizures during “early life can alter neuronal excitability long-
term.” Id. at 1286. That is, “brain inflammation . . . appears to be responsible for these long-
term neurological changes.” Id. The “epileptic process” is described “as a disturbance of
neuronal networks.” Pet. Ex. 23 at 33.18 Studies by Birca et al. and others “favor[] the
hypothesis that connectivity changes are a consequence of atypical febrile seizures.” Id. at 37.
Respondent’s expert, Dr. Holmes, co-authored an article with Dr. Yehezkel Ben-Ari,
which Dr. Kinsbourne also cites in support of his causal theory. The authors state that
“increasing experimental animal data strongly suggest that frequent or prolonged seizures in the
developing brain result in long-lasting sequelae.” Pet. Ex. 34 at 1055.19 During febrile seizures,
pro-inflammatory cytokines increase, and these cytokines are thought to play a role “in febrile-
seizure-induced changes in the brain.” Id. at 1056. Experimental studies show that prolonged
febrile seizures may cause “long-standing increased excitability.” Id. Thus, the traditional idea
that “seizures beget seizures” has received modern support. Id. at 1059-60.
In addition to opining that B.F.’s March 12, 2014 DTaP vaccine triggered the onset of
B.F.’s seizure disorder, Dr. Kinsbourne also asserts that the MMR vaccine B.F. received on
September 18, 2014 significantly aggravated her epilepsy disorder. Pet. Ex. 52 at 3. Prior to her
MMR vaccine, B.F. had a three-month seizure-free interval. Id. He states that B.F.’s case meets
the criteria for a significant aggravation because “prior to the administration of the MMR
vaccine, [B.F.’s] seizures had been controlled by anti-epileptic monotherapy,” but following the
MMR vaccine, she had six seizures over a three-month period, and “her seizures became harder
to control . . . to the point that her epilepsy was declared ‘intractable.’” Pet. Ex. 21 at 2, 5; see
also Pet. Ex. 52 at 3; Tr. 45-46.
17 Annamaria Vezzani et al., IL-1 Receptor/Toll-like Receptor Signaling in Infection,
Inflammation, Stress and Neurodegeneration Couples Hyperexcitability and Seizures, 25 Brain
Behav. & Immunity 1281 (2011).
18 A. Birca et al., Enhanced EEG Connectivity in Children with Febrile Seizures, 110 Epilepsy
Res. 32 (2015).
19 Yehezkel Ben-Ari & Gregory L. Holmes, Effects of Seizures on Developmental Processes in
the Immature Brain, 5 Lancet Neurology 1055 (2006).
12

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 13 of 24
Dr. Kinsbourne argues that there is a “causal relationship” between B.F.’s September 18,
2014 MMR vaccine and her September 25, 2014 seizure because “the risk interval for a seizure
after MMR has been considered to be the second week after vaccination,” and the seven-day
period between B.F.’s vaccination and seizure is “within the acknowledged risk interval.” Pet.
Ex. 51 at 3; see also Tr. 48. He concludes that because “[t]he MMR vaccination initiated a
sequence of events not explicable by any other factor,” B.F.’s September 18, 2014 MMR
vaccination “cause[d] the significant aggravation of [B.F.’s] seizure disorder by inducing a
complex seizure.” Pet. Ex. 21 at 5.
With regard to B.F.’s current condition, Dr. Kinsbourne opines that she has focal
epilepsy, and that her EEG from November 2017 shows a primary epileptogenic focus in the
right hemisphere with secondary generalization. Tr. 77-78, 87-90; see Pet. Ex. 48 at 92.
2. Respondent – Dr. Gregory Holmes, M.D.
a. Background and Qualifications
Dr. Holmes earned his B.S. from Washington and Lee University and his M.D. from the
University of Virginia School of Medicine. Resp. Ex. B at 1. From 1979 to 1986, Dr. Holmes
was a Staff Neurologist at Newington Children’s Hospital and John Dempsey Hospital. Id. at 2.
He became the Director of the Pediatric Epilepsy Program at Talmadge Hospital in 1986 and
remained in there until 1988. Id. From 1988 to 2002, Dr. Holmes held a number of positions at
Boston Children’s Hospital, including Director of the Clinical Neurophysiology Laboratory and
Epilepsy Program and Director of the Center for Research in Pediatric Epilepsy. Id. He is
currently the Physician Leader of the Neurology Health Care Service at Fletcher Allen Health
Care. Id. Dr. Holmes is board certified in pediatrics, clinical neurophysiology, and psychiatry
and neurology, with special competence in child neurology. Id. at 1. Dr. Holmes is licensed in
Connecticut, Georgia, Massachusetts, New Hampshire, and Vermont. Id. He is active in a
number of professional organizations and serves on several editorial boards, including Epilepsy
& Behavior and Epileptic Disorders. Id. at 7, 11-13. Dr. Holmes has written extensively on a
number of topics; his CV lists him as the author or co-author of more than 300 publications and
nearly 400 abstracts. Id. at 39-112.
b. Opinion
Dr. Holmes begins by explaining that “[t]he medical record does not support the idea that
[B.F.’s] epilepsy was caused by vaccines,” particularly because B.F. tested positive for RSV at
the time of her initial seizure and RSV is “well known to cause febrile seizures.” Resp. Ex. A at
11. He further alleges that there is “no indication in the medical record that vaccines exacerbated
[B.F.’s] condition.” Id. Dr. Holmes opines that “it is not unusual for the cause of the epilepsy to
be unknown,” as he believes it is in B.F.’s case. Id. He also notes that “none of [B.F.’s]
caretakers endorsed the idea that [her] epilepsy is secondary to vaccination.” Id. Dr. Holmes
agrees with Dr. Kinsbourne that B.F. has focal epilepsy with secondary generalization, but
13

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 14 of 24
believes the etiology is probably genetic20 and thus, her condition pre-existed the vaccinations at
issue. Tr. 143.
Dr. Holmes addresses each of Dr. Kinsbourne’s assertions individually. He first states
that Dr. Kinsbourne “provide[d] no evidence that a vaccination resulted in the febrile seizure in
[B.F.] or that a 10-minute febrile seizure resulted in epilepsy.” Resp. Ex. A at 11. Similarly, Dr.
Holmes finds “no evidence that the vaccinations [B.F.] received had any relationship to the
subsequent development of epilepsy.” Id. He notes that “[t]he link between DTaP and seizures
of any type is weak,” and it is unlikely that the vaccine would result in febrile seizures. Id.
According to Dr. Holmes, even if B.F.’s vaccinations did in fact cause a febrile seizure, “there is
no evidence that this seizure would cause epilepsy.” Id. Dr. Holmes concludes that “even if one
uses 10 minutes to define a complex febrile [seizure] there is no evidence that a 10 minute febrile
seizure[] would cause epilepsy.” Id. at 12. He defines a complex seizure as fifteen minutes in
duration, focal,21 or two or more seizures in twenty-four hours. Tr. 145.
Dr. Holmes opines that febrile seizures do not cause epilepsy unless they are focal or 30
minutes or longer (status epilepticus). Tr. 145-46, 162. Dr. Holmes states that the risk of
developing epilepsy after a simple febrile seizure is only 2%. Tr. 146 (citing Resp. Ex. A, Tab
10 at 1-2).22 However, if a child has a complex febrile seizure, the risk of epilepsy is higher. Tr.
147. He agrees that fever reduces the seizure threshold, but points to other triggers such as
decreased sleep that also reduce the threshold. Tr. 156. While Hesdorffer uses ten minutes as
the cutoff for a complex seizure, Dr. Holmes opines that the majority of physicians use a fifteen-
minute cutoff. Tr. 157. He explained that “biologically, there is no evidence that a ten-minute
seizure is any different than a 15-minute seizure.” Tr. 160. Dr. Holmes concludes that B.F. had
a simple febrile seizure lasting approximately ten minutes, and that it is biologically implausible
for a seizure lasting ten minutes to cause brain damage or epilepsy. Tr. 159, 162, 170.
Dr. Holmes agreed with Dr. Kinsbourne that there can be functional changes after a
seizure, but that does not mean that a child will develop epilepsy. Tr. 173. He believes that only
prolonged or frequent seizures affect the neuronal network. Tr. 174-75. Quoting Berg and
Shinnar, Dr. Holmes concludes that “brief seizures . . . do not appear to result in an escalating
progressive syndrome leading to a permanent epileptic focus.” Tr. 179 (quoting Resp. Ex. G,
Tab 6 at 10).23 Moreover, he opines that the simple seizure B.F. experienced on March 15, 2014
20 During the pendency of this claim, respondent was asked to consult with his expert, Dr.
Holmes, as to whether genetic testing should be performed. Order dated July 11, 2017 (ECF No.
49). Dr. Holmes and petitioner’s treating physician, Dr. MacDonald, agreed that genetic testing
was not indicated in this case. Resp. Status Rept., filed Aug. 10, 2017, at 1.
21 A focal seizure is a partial seizure. Dorland’s Illustrated Medical Dictionary 1688 (32d ed. 2012).
22 Karen B. Nelson & Jonas H. Ellenberg, Predictors of Epilepsy in Children Who Have
Experienced Febrile Seizures, 295 New Eng. J. Med. 1029 (1976).
23 Anne T. Berg & Shlomo Shinnar, Do Seizures Beget Seizures? An Assessment of the Clinical
(. . . continued)
14

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 15 of 24
was probably caused by RSV, not vaccination. Tr. 185-86. Dr. Holmes testified that if B.F.’s
initial seizure was partial or focal, her seizure would have met the criteria for a complex seizure.
Tr. 204. He agrees that some of the seizures she had in 2014 could have been focal with
secondary generalization. Tr. 203-04.
Next, Dr. Holmes responds to the significant aggravation claim. He concedes that “[t]he
MMR vaccine is associated with an increased risk for febrile seizures, and it is possible that the
febrile seizure on 9/25/14 was related to the immunization.” Resp. Ex. A at 13. However, he
highlights that “[B.F.] had multiple febrile seizures not associated with immunizations.” Id. He
also notes that Dr. Kinsbourne did not provide any “epidemiologic or mechanistic evidence” that
a complex febrile seizure can significantly aggravate epilepsy. Resp. Ex. E at 3. Dr. Holmes
explains that studies have “found no increased rate of epilepsy among children who had febrile
seizures after MMR,” as compared to those who had febrile seizures unrelated to vaccinations.
Resp. Ex. A at 13 (quoting Resp. Ex. A, Tab 42, at 5).24
Dr. Holmes also opines that although B.F. had a febrile seizure seven days after receiving
the MMR vaccine, she did not have another seizure for almost two months, and thus “there is no
record of exacerbation.” Resp. Ex. A at 13. Critically, Dr. Holmes notes that “fluctuations in
seizure frequency is common in epilepsy,” and do not necessarily indicate a causal connection
between the MMR vaccine and the subsequent seizure. Resp. Ex. E at 3.
3. Respondent – Dr. Hayley Gans, M.D.
a. Background and Qualifications
Dr. Gans earned her B.A. from Connecticut College and her M.D. from SUNY Health
Science Center at Syracuse. Resp. Ex. D at 1. Dr. Gans completed her post-graduate training at
Stanford University School of Medicine in 1998 and has remained at Stanford since that time.
Id. at 1-2. She is currently a Clinical Associate Professor in the Department of Pediatrics. Id. at
2. Dr. Gans is a licensed physician in the state of California, and she is board-certified in
pediatrics and pediatric infectious diseases. Id. at 1. Dr. Gans has authored or co-authored
nearly thirty peer reviewed articles and more than twenty abstracts. Id. at 4-6.
b. Opinion
Dr. Gans opines that B.F.’s March 12, 2014 vaccination did not cause or substantially
contribute to her initial febrile seizure or epilepsy. Tr. 99. Instead, Dr. Gans believes B.F.’s
RSV infection “is more probable as the cause of the neurologic disease than the immunization
which would only be temporally related and even this timing is not supported.” Resp. Ex. C at 5.
Dr. Gans describes the potential mechanisms through which RSV can cause seizure activity,
Evidence in Humans, 14 J. Clinical Neurophysiology 102 (1997).
24 Mogens Vestergaard et al., MMR Vaccination and Febrile Seizures: Evaluation of Susceptible
Subgroups and Long-Term Prognosis, 292 JAMA 351 (2004).
15

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 16 of 24
explaining that “[RSV] can activate mediators of inflammation, including cytokines . . . which
have been shown to have direct and indirect effects on neuronal activity and to be correlated with
neurological complications, including seizures.” Id. at 6. Dr. Gans also explains that B.F.’s
“normal neurological evaluations” and “mildly abnormal EEG” after her initial seizure were
“very consistent with the seizures and diagnostic testing results seen with RSV infection.” Id. at
7.
Dr. Gans disputes the claim that the DTaP vaccine may cause a febrile seizure three days
after administration. Resp. Ex. C at 7. She states that “[i]n studies that have shown a temporal
association with [febrile seizures and DTaP,] these have all occurred within 2 days and mostly on
[the] day of vaccine administration.” Id. Dr. Gans highlights that B.F. received “non-live” viral
vaccines on March 12, 2014 and experienced a “complex (10 minute) febrile seizure” on March
15, 2014, three days later, “which is beyond the range for the risk period for seizures associated
with these vaccines.” Id. Dr. Gans also notes that B.F. “received the same vaccines at 2 and 4
months of age prior to 9 month administration without incident,” and “[a]dverse events typically
occur after the primary dose and not after several doses have been given without any reaction.”
Id.
While the studies cited by Dr. Gans showed no increased risk for seizures three days after
DTaP vaccination, these findings were subject to limitations and confounding factors:
misclassification and incomplete data for febrile seizures; the size of the study population; use of
automated data that was sometimes inconsistent with medical records; the presence of fever that
was poorly documented, thus febrile seizures were not completely and accurately documented;
and increased use of acetaminophen/paracetamol, used to reduce fever after vaccination. Resp.
Ex. F, Tab 1, at 6-8; Resp. Ex. F, Tab 2, at 5-6; Resp. Ex. F, Tab 3 at 6.25
During the hearing, Dr. Gans stated that she would “leave it to the neurologist [Dr.
Holmes]” to discuss the epilepsy aspect of B.F.’s case. Tr. 119. However, Dr. Gans opines that
“there is no evidence in the studies associating seizures with immunization to support the
subsequent diagnosis of epilepsy.” Resp. Ex. C at 8. Dr. Gans disagrees that the MMR vaccine
B.F. received aggravated her seizure disorder, because she “suffered many seizures mostly
associated with acute illnesses . . . with or without the administration of vaccines,” and thus any
“temporal association of vaccination with any given seizure event would be arbitrary.” Id.; see
also Tr. 99. Dr. Gans posits that the fact that “BF developed epilepsy and subsequently had
many additional seizures often incited by infectious etiologies” is a “common event” that could
“be predicted by [B.F.’s] risk factors alone,” independent of any vaccinations. Resp. Ex. H at 3;
Resp. Ex. C at 8.
On cross-examination, Dr. Gans testified that she could not say whether RSV, fever, or
the combination caused B.F.’s first seizure on March 15, 2014. Tr. 122-23. Dr. Gans also
agreed that the DTaP vaccine causes fever. Tr. 128. The mechanism by which DTaP causes
25 Nick Andrews et al., Post-licensure Comparison of the Safety Profile of
Diphtheria/Tetanus/Whole Cell Pertussis/Haemophilus Influenza Type B Vaccine and a 5-in-1
Diphtheria/Tetanus/Acellular Pertussis/Haemophilus Influenza Type B/Polio Vaccine in the
United Kingdom, 28 Vaccine 7215 (2010).
16

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 17 of 24
fever is due to the immune response to the vaccine, which includes pro-inflammatory cytokines,
and is “highly associated with fever.” Tr. 128-29. She opines that RSV triggers fever in the
same way. Tr. 129.
III. DISCUSSION
A. Standards for Adjudication
The Vaccine Act was established to compensate vaccine-related injuries and deaths.
§300aa-10(a). “Congress designed the Vaccine Program to supplement the state law civil tort
system as a simple, fair and expeditious means for compensating vaccine-related injured persons.
The Program was established to award ‘vaccine-injured persons quickly, easily, and with
certainty and generosity.’” Rooks v. Sec’y of Health & Human Servs., 35 Fed. Cl. 1, 7 (1996)
(quoting H.R. Rep. No. 908 at 3, reprinted in 1986 U.S.C.C.A.N. at 6287, 6344).
Petitioner’s burden of proof is by a preponderance of the evidence. § 300aa-13(a)(1).
The preponderance standard requires a petitioner to demonstrate that it is more likely than not
that the vaccine at issue caused the injury. Moberly v. Sec’y of Health & Human Servs., 592
F.3d 1315, 1322 n.2 (Fed. Cir. 2010). Proof of medical certainty is not required. Bunting v.
Sec’y of Health & Human Servs., 931 F.2d 867, 873 (Fed. Cir. 1991). In particular, petitioner
must prove that the vaccine was “not only [the] but-for cause of the injury but also a substantial
factor in bringing about the injury.” Moberly, 592 F.3d at 1321 (quoting Shyface v. Sec’y of
Health & Human Servs., 165 F.3d 1344, 1352-53 (Fed. Cir. 1999)); see also Pafford v. Sec’y of
Health & Human Servs., 451 F.3d 1352, 1355 (Fed. Cir. 2006). A petitioner who satisfies this
burden is entitled to compensation unless respondent can prove, by a preponderance of the
evidence, that the vaccinee’s injury is “due to factors unrelated to the administration of the
vaccine.” § 300aa-13(a)(1)(B).
B. Factual Issues
A petitioner must prove, by a preponderance of the evidence, the factual circumstances
surrounding her claim. 42 U.S.C. § 300aa–13(a)(1)(A). To resolve factual issues, the special
master must weigh the evidence presented, which may include contemporaneous medical records
and testimony. See Burns v. Sec’y of Health & Human Servs., 3 F.3d 415, 417 (Fed. Cir. 1993)
(explaining that a special master must decide what weight to give evidence including oral
testimony and contemporaneous medical records). Contemporaneous medical records are
presumed to be accurate. See Cucuras v. Sec’y of Health & Human Servs., 993 F.2d 1525, 1528
(Fed. Cir. 1993). To overcome the presumptive accuracy of medical records, a petitioner may
present testimony which is “consistent, clear, cogent, and compelling.” Sanchez v. Sec’y of
Health & Human Servs., No. 11–685V, 2013 WL 1880825, at *3 (Fed. Cl. Spec. Mstr. Apr. 10,
2013) (citing Blutstein v. Sec’y of Health & Human Servs., No. 90–2808V, 1998 WL 408611, at
*5 (Fed. Cl. Spec. Mstr. June 30, 1998)).
There are situations in which compelling testimony may be more persuasive than written
records, such as where records are deemed to be incomplete or inaccurate. Campbell v. Sec’y of
Health & Human Servs., 69 Fed. Cl. 775, 779 (2006) (“[L]ike any norm based upon common
17

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 18 of 24
sense and experience, this rule should not be treated as an absolute and must yield where the
factual predicates for its application are weak or lacking.”); Lowrie v. Sec’y of Health & Human
Servs., No. 03-1585V, 2005 WL 6117475, at *19 (Fed. Cl. Spec. Mstr. Dec. 12, 2005)
(“[W]ritten records which are, themselves, inconsistent, should be accorded less deference than
those which are internally consistent.” (quoting Murphy v. Sec’y of Health & Human Servs., 23
Cl. Ct. 726, 733 (1991), aff’d per curiam, 968 F.2d 1226 (Fed. Cir. 1992))). Ultimately, a
determination regarding a witness’s credibility is needed when determining the weight that such
testimony should be afforded. Andreu v. Sec’y of Health & Human Servs., 569 F.3d 1367, 1379
(Fed. Cir. 2009); Bradley v. Sec’y of Health & Human Servs., 991 F.2d 1570, 1575 (Fed. Cir.
1993).
Despite the weight afforded medical records, special masters are not bound rigidly by
those records in determining onset of a petitioner’s symptoms. Valenzuela v. Sec’y of Health &
Human Servs., No. 90-1002V, 1991 WL 182241, at *3 (Fed. Cl. Spec. Mstr. Aug. 30, 1991); see
also Eng v. Sec’y of Health & Human Servs., No. 90-1754V, 1994 WL 67704, at *3 (Fed. Cl.
Spec. Mstr. Feb. 18, 1994) (Section 13(b)(2) “must be construed so as to give effect also to §
13(b)(1) which directs the special master or court to consider the medical records (reports,
diagnosis, conclusions, medical judgment, test reports, etc.), but does not require the special
master or court to be bound by them”).
C. Causation
To receive compensation through the Program, petitioner must prove either (1) that B.F.
suffered a “Table Injury”—i.e., an injury listed on the Vaccine Injury Table—corresponding to a
vaccine that she received, or (2) that B.F. suffered an injury that was actually caused by a
vaccination. See §§ 300aa-13(a)(1)(A), 11(c)(1); Capizzano v. Sec’y of Health & Human Servs.,
440 F.3d 1317, 1319-20 (Fed. Cir. 2006). Because petitioner does not allege that B.F. suffered a
Table Injury, she must prove that a vaccine B.F. received caused her injury. To do so, she must
establish, by preponderant evidence: (1) a medical theory causally connecting the vaccine and
B.F.’s injury (“Althen Prong One”); (2) a logical sequence of cause and effect showing that the
vaccine was the reason for B.F.’s injury (“Althen Prong Two”); and (3) a showing of a proximate
temporal relationship between the vaccine and B.F.’s injury (“Althen Prong Three”). § 300aa–
13(a)(1); Althen, 418 F.3d at 1278.
The causation theory must relate to the injury alleged. The petitioner must provide a
sound and reliable medical or scientific explanation that pertains specifically to this case,
although the explanation need only be “legally probable, not medically or scientifically certain.”
Knudsen v. Sec’y of Health & Human Servs., 35 F.3d 543, 548-49 (Fed. Cir. 1994). Petitioner
cannot establish entitlement to compensation based solely on her assertions; rather, a vaccine
claim must be supported either by medical records or by the opinion of a medical doctor. §
300aa-13(a)(1). In determining whether petitioner is entitled to compensation, the special master
shall consider all material in the record, including “any . . . conclusion, [or] medical judgment . .
. which is contained in the record regarding . . . causation.” § 300aa-13(b)(1)(A). The
undersigned must weigh the submitted evidence and the testimony of the parties’ proffered
experts and rule in petitioner’s favor when the evidence weighs in her favor. See Moberly, 592
F.3d at 1325-26 (“Finders of fact are entitled—indeed, expected—to make determinations as to
18

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 19 of 24
the reliability of the evidence presented to them and, if appropriate, as to the credibility of the
persons presenting that evidence.”); Althen, 418 F.3d at 1280 (noting that “close calls” are
resolved in petitioner’s favor).
D. Analysis of Factual Issues
In their joint prehearing submission, the parties identify a number of issues that require
resolution. Generally, these issues will be resolved in the causation analysis discussion below.
However, one issue is factual in nature, and will be discussed here: whether the 10-minute
seizure that B.F. suffered on March 15, 2014 was a “complex” seizure. The undersigned finds
that the seizure B.F. suffered on March 15, 2014 was a “complex” seizure based on expert
opinion, medical literature, medical records, and records of treating physicians.
Both Dr. Kinsbourne and B.F.’s treating physicians classify B.F.’s March 15, 2014
seizure as complex. Dr. Kinsbourne suggests seizures that last at least ten minutes, like B.F.’s
March 15, 2014 seizure, are complex. Tr. 33; Pet. Ex. 21 at 4. Although Dr. Kinsbourne
acknowledged that “the cut-off point between a simple and a complex febrile seizure has often
been set at 15 minutes, recent studies have favored a shorted time span.” Pet. Ex. 33 at 2. For
example, articles by Hesdorffer and Trinka found prolonged, complex seizures are more than ten
and seven minutes respectively, supporting Dr. Kinsbourne’s position. Pet. Ex. 39 at 6; Resp.
Ex. A, Tab 21 at 3.
In her expert report, Dr. Gans cites to notes from treating physicians, Dr. MacDonald and
Dr. Robert Parkey, which label B.F.’s March 15, 2014 seizure as complex. Resp. Ex. C at 4.
Specifically, Dr. MacDonald assessed B.F. with complex febrile seizures and Dr. Parkey noted
B.F.’s “prolonged initial febrile seizure on [March 15, 2014]” during a later visit. Pet. Ex. 3 at
107, 115. Dr. Parkey noted B.F.’s “seizures seem atypical.” Id. at 104. Dr. Theodore Krisher,
the emergency room consulting physician on March 15, 2014, also noted B.F.’s seizure was
atypical and “prolonged.” Id. at 75.
Although Dr. Holmes opines that B.F.’s initial seizure on March 15, 2014 was a simple
febrile seizure, the undersigned finds the evidence does not support his opinion. According to
Dr. Holmes, most physicians use a fifteen-minute cutoff. However, as Dr. Holmes testified,
“biologically, there is no evidence that a ten-minute seizure is any different than a 15-minute
seizure.” Tr. 160. In fact, in a supplemental report, Dr. Holmes cites an article by Berg and
Shinnar, which notes that both ten and fifteen minutes have been used to describe complex
seizures. Resp. Ex. E, Tab 5 at 1. However, Berg and Shinnar chose to define “[a] seizure [as]
prolonged if it lasted [more than or equal to] 10 min[utes].” Id. at 2.
Although both ten and fifteen minutes have been used to differentiate between a simple
and complex seizure, recent studies have used ten minutes. Because B.F.’s initial seizure was
approximately ten minutes in length, and described as atypical and prolonged, the undersigned
concludes that B.F. suffered a complex seizure on March 15, 2014.
19

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 20 of 24
E. Causation Analysis
1. Althen Prong One
Under Althen Prong One, petitioner must set forth a medical theory explaining how the
received vaccine could have caused the sustained injury. Andreu, 569 F.3d at 1375; Pafford, 451
F.3d at 1355-56. Petitioner’s theory of causation need not be medically or scientifically certain,
but it must be informed by a “sound and reliable medical or scientific explanation.” Knudsen, 35
F.3d at 548; see also Veryzer v. Sec’y of Health & Human Servs., 98 Fed. Cl. 214, 223 (2011)
(noting that special masters are bound by both § 13(b)(1) and Vaccine Rule 8(b)(1) to consider
only evidence that is both “relevant” and “reliable”). If petitioner relies upon a medical opinion
to support her theory, the basis for the opinion and the reliability of that basis must be considered
in the determination of how much weight to afford the offered opinion. See Broekelschen v.
Sec’y of Health & Human Servs., 618 F.3d 1339, 1347 (Fed. Cir. 2010) (“The special master’s
decision often times is based on the credibility of the experts and the relative persuasiveness of
their competing theories.”); Perreira v. Sec’y of Health & Human Servs., 33 F.3d 1375, 1377 n.6
(Fed. Cir. 1994) (stating that an “expert opinion is no better than the soundness of the reasons
supporting it” (citing Fehrs v. United States, 620 F.2d 255, 265 (Ct. Cl. 1980))).
Petitioner has proffered preponderant evidence of a plausible medical theory. The first
tenet of Dr. Kinsbourne’s medical theory is that vaccination can cause the release of pro-
inflammatory cytokines, which can trigger complex febrile seizures. Petitioner provided current
medical support for this theory. To summarize, Dr. Kinsbourne explains that “[v]accinations
activate the innate immune system, which enables adaptive immunity to develop,” by stimulating
the release of pro-inflammatory cytokines. Pet. Ex. 21 at 4. When the cytokine release is
excessive, seizures can occur. Tr. 35. Vaccine-associated release of pro-inflammatory cytokines
is operative in a case where the seizure occurs within a medically reasonable temporal interval.
Pet. Ex. 21 at 3-4. Dr. Kinsbourne testified DTaP vaccination is operative in a case where a
seizure occurs within three days after the date of administration, which is defined as day zero.
Tr. 33-35.
The second tenet of Dr. Kinsbourne’s theory is that “seizures beget seizures.” In a subset
of children, the first seizure causes changes in the brain, such that further seizures may be more
likely. In support of this theory, Dr. Kinsbourne cites Dr. MacDonald’s notes, in which he wrote
that with each complex seizure, it is more likely that another such seizure will occur. Tr. 43-44
(citing Pet. Ex. 16 at 4). Dr. Kinsbourne also cites various articles in support of his theory that
seizures beget seizures, which can eventually lead to epilepsy. See, e.g., Pet. Exs. 23, 28, 32, 34,
39. For example, Hesdorffer writes “prolonged febrile seizures are associated with an increased
risk of developing epilepsy.” Pet. Ex. 39 at 6. Feng and Chen explain that the release of
cytokines “contribute[] not only to the generation of [febrile seizures], but also to the
epileptogenesis thereafter.” Pet. Ex. 28 at 482. In their article, Ben-Ari and Holmes quote
William Gowers, a distinguished neurologist, who stated, “[t]he tendency of the disease
[epilepsy] is to self-perpetuation; each attack facilitates the occurrence of another, by increasing
the instability of the nerve elements.” Pet. Ex. 34 at 1059. Ben-Ari and Holmes provide support
that prolonged febrile seizures may cause “long-standing increased excitability.” Id. at 1056.
20

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 21 of 24
While respondent relies heavily on statistical significance in arguing against Dr.
Kinsbourne’s theory, the undersigned is not bound by statistical data in this context where B.F.
was ultimately diagnosed with epilepsy. Accordingly, the undersigned finds Dr. Kinsbourne
credible, and with Dr. MacDonald’s notes and supporting medical literature, petitioner has set
forth a sound and reliable medical theory, satisfying Althen Prong One.
2. Althen Prong Two
Under Althen Prong Two, petitioner must prove by a preponderance of the evidence that
there is a “logical sequence of cause and effect showing that the vaccination was the reason for
the injury.” Capizzano, 440 F.3d at 1324 (quoting Althen, 418 F.3d at 1278). “Petitioner must
show that the vaccine was the ‘but for’ cause of the harm . . . or in other words, that the vaccine
was the ‘reason for the injury.’” Pafford, 451 F.3d at 1356 (internal citations omitted).
In evaluating whether this prong is satisfied, the opinions and views of the vaccinee’s
treating physicians are entitled to some weight. Andreu, 569 F.3d at 1367; Capizzano, 440 F.3d
at 1326 (“[M]edical records and medical opinion testimony are favored in vaccine cases, as
treating physicians are likely to be in the best position to determine whether a ‘logical sequence
of cause and effect show[s] that the vaccination was the reason for the injury.’” (quoting Althen,
418 F.3d at 1280)). Medical records are generally viewed as trustworthy evidence, since they are
created contemporaneously with the treatment of the vaccinee. Cucuras, 993 F.2d at 1528. The
petitioner need not make a specific type of evidentiary showing, i.e., “epidemiologic studies,
rechallenge, the presence of pathological markers or genetic predisposition, or general
acceptance in the scientific or medical communities to establish a logical sequence of cause and
effect.” Capizzano, 440 F.3d at 1325. Instead, petitioner may satisfy her burden by presenting
circumstantial evidence and reliable medical opinions. Id. at 1325–26.
The experts agree that the first seizure was triggered by a fever. Tr. 43 (Dr. Kinsbourne),
214-15 (Dr. Holmes). However, Dr. Kinsbourne opines the DTaP vaccine contributed to B.F.’s
seizure, while Dr. Holmes believes the RSV infection likely caused the initial seizure. As a
foundational matter, it is important to note that “respondent accepts that the DTaP vaccine can
cause a fever, which in turn can cause a febrile seizure.” Resp. Posthr’g Br., filed May 3, 2019,
at 19 (citing Resp. Ex. A at 11); see also Tr. 117-18, 128-29. The issue here is whether the DTaP
vaccination was a substantial contributing factor to B.F.’s initial seizure.
The undersigned finds petitioner provided preponderant evidence that the DTaP
vaccination B.F. received on March 12, 2014 was a substantial contributing factor to her initial
seizure on March 15, 2014. Dr. Kinsbourne opines, and the medical literature supports, that
DTaP vaccinations can cause febrile seizures three days after administration. Tr. 33-35, 94; see
21

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 22 of 24
Pet. Exs. 36, 37,26 40,27 41, 61;28 Resp. Ex. F, Tab 1 at 5 tbl.2. As discussed above, the date of
vaccination is considered “day zero,” which is supported by medical literature presented by both
petitioner and respondent. See Pet. Ex. 36 at 4; Resp. Ex. F, Tab 1 at 3. Thus, B.F.’s initial
seizure on March 15, 2014 occurred on “day three.” Because B.F.’s initial seizure occurred on
day three, Dr. Kinsbourne argues that the vaccination was a substantial contributing factor to
B.F.’s initial seizure since it occurred in a medically reasonable temporal interval. Pet. Ex. 21 at
3-4.
Dr. Holmes opines that the RSV infection likely caused B.F.’s initial seizure. Dr.
Holmes notes RSV is well known to cause febrile seizures. Resp. Ex. A at 11. Dr. Gans adds
that “[RSV] can activate mediators of inflammation, including cytokines,” similar to the
inflammatory response that occurs after vaccination. Resp. Ex. C at 6; Tr. 128-29. However, as
Dr. Gans testified, it is impossible to differentiate the exact cause of the first seizure “when a
child presents with an infection that has neurologic complications as well as a fever.” Tr. 122-
23. Dr. Kinsbourne concedes that RSV could have played a role in the cause of the first seizure
but opines that it is not the sole cause because the RSV infection was longstanding, and B.F. had
her initial seizure only after vaccination. Tr. 44; Pet Ex. 21 at 3. He believes that the combined
effect of the underlying RSV infection with the vaccination caused B.F.’s initial seizure. Tr. 81-
82. Although B.F. did not appear sick on the date of vaccination, Dr. Gans testified that an RSV
infection can be asymptomatic. Tr. 125.
The undersigned finds B.F.’s DTaP vaccination was a substantial factor in causing B.F.’s
initial seizure. See Shyface, 165 F.3d at 1352-53 (finding petitioner must prove “that the vaccine
was not only a but-for cause of the injury but also a substantial factor in bringing about the
injury”). In Shyface, although the petitioner did not prove the vaccine to be the sole cause of the
injury, “the requirements of the Vaccine Act [were] met prima facie upon proof of the substantial
factor criterion.” Id. at 1353. Thus, petitioner does not need to prove the DTaP vaccine was the
sole cause of B.F. condition, only that it was a but-for cause as well as a substantial factor in
bringing about B.F.’s condition.
26 Dennis A. Conrad & Hal B. Jensen, Using Acellular Pertussis Vaccines for Childhood
Immunization: Potential Benefits Far Outweigh Potential Risks, 105 Postgraduate Med. 165
(1999).
27 Lisa A. Jackson et al., Retrospective Population-Based Assessment of Medically Attended
Injection Site Reactions, Seizures, Allergic Responses and Febrile Episodes After Acellular
Pertussis Vaccine Combines with Diphtheria and Tetanus Toxoids, 21 Pediatric Infectious
Disease J. 781 (2002).
28 M.A. Überall et al., Severe Adverse Events in a Comparative Efficacy Trial in Germany in
Infants Receiving Either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP)
Vaccine, the Lederle Whole-Cell Component DTP (DTP) or DT Vaccine, 89 Dev. Biological
Standardization 83 (1999).
22

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 23 of 24
Regardless of whether the RSV infection attributed to B.F.’s initial seizure, it is not the
sole cause. As petitioner explained, B.F.’s initial seizure occurred only after administration of
the DTaP vaccine and within a medically recognized time frame. The DTaP vaccine is known to
cause seizures within three days of administration, which occurred here. Simply because B.F.
tested positive for RSV on the date of vaccination does not preclude the finding that the vaccine
was a substantial contributing factor in B.F.’s initial seizure. Although the March 12, 2014
vaccination was B.F.’s third dose of DTaP, and B.F. had no adverse reactions from previous
vaccinations, studies have shown “[r]ates of fever [are] highest after DTaP [is] given as the third
and fourth doses.” Pet. Ex. 40 at 783. Petitioner has demonstrated a “logical sequence of cause
and effect showing that the vaccination was the reason for the injury.” Capizzano, 440 F.3d at
1324 (quoting Althen, 418 F.3d at 1278).
As discussed previously under Althen Prong One, Dr. Kinsbourne opines that seizures
beget seizures, which can lead to epilepsy. He argues that B.F.’s initial seizure likely contributed
to her epilepsy because complex febrile seizures are more likely to lead to more seizures and
epilepsy. Tr. 38-39. Dr. Holmes agrees that the “risk of epilepsy following a febrile seizure is
higher than in children without febrile seizures.” Resp. Ex. G at 1; see also Resp. Ex. A, Tab 10
at 1 (noting that “[a]ll relevant studies agree that children who have had one or more febrile
seizures are more likely to become epileptic than children who have had no febrile seizures”).
Dr. Holmes also agrees that there can be functional changes after a seizure. Tr. 171-73. He
testified that “seizures can change the brain and perhaps make them more susceptible to seizures,
but it doesn’t necessarily lead to epilepsy.” Tr. 210. Dr. Holmes believes that only prolonged or
frequent seizures affect the neuronal network. Tr. 173-74. He also argues that some no longer
view complex febrile seizures as the cause of the development of epilepsy. Tr. 146-48.
However, as briefly discussed in Althen Prong One, numerous medical articles describe
febrile seizures as a potential cause of epilepsy. As Dr. Holmes testified, risk of epilepsy follows
a simple febrile seizure, but the risk is higher after a child has a complex febrile seizure. Tr. 146-
47. In fact, Dr. Holmes stated, “[i]f you have one prolonged febrile seizure, you may have
another prolonged febrile seizure.” Tr. 149. As the undersigned has already determined, B.F.’s
initial seizure was complex. Additionally, the medical records show that B.F. suffered other
complex, prolonged seizures. See Pet Ex. 3 at 88-89, 117; Pet. Ex. 11 at 24.
The undersigned found petitioner’s Althen Prong One theory persuasive and now finds
petitioner, by preponderant evidence, has shown that the DTaP vaccine was the reason for B.F.’s
initial seizure and epilepsy. Accordingly, petitioner has satisfied Althen Prong Two.
3. Althen Prong Three
Althen Prong Three requires petitioner to establish a “proximate temporal relationship”
between the vaccination and the injury alleged. Althen, 418 F.3d at 1281. That term has been
equated to mean a “medically acceptable temporal relationship.” Id. The petitioner must offer
“preponderant proof that the onset of symptoms occurred within a timeframe which, given the
medical understanding of the disease’s etiology, it is medically acceptable to infer causation-in-
fact.” De Bazan v. Sec’y of Health & Human Servs., 539 F.3d 1347, 1352 (Fed. Cir. 2008).
The explanation for what is a medically acceptable time frame must also coincide with the
23

Case 1:15-vv-01470-UNJ Document 142 Filed 01/14/20 Page 24 of 24
theory of how the relevant vaccine can cause the injury alleged (under Althen Prong One). Id.;
Koehn v. Sec’y of Health & Human Servs., 773 F.3d 1239, 1243 (Fed. Cir. 2014); Shapiro v.
Sec’y of Health & Human Servs., 101 Fed. Cl. 532, 542 (2011), recons. den’d after remand,
105 Fed. Cl. 353 (2012), aff’d mem., 503 F. App’x 952 (Fed. Cir. 2013).
The undersigned finds petitioner provided preponderant evidence of a proximate
temporal relationship between B.F.’s March 12, 2014 DTaP vaccination and B.F.’s March 15,
2014 complex febrile seizure. As discussed above, DTaP vaccinations can cause febrile
seizures three days after administration. Because B.F.’s initial seizure occurred on day three,
the undersigned finds petitioner established a medically acceptable time frame.
F. Alternative Causation
Because the undersigned concludes that petitioner has established a prima facie case,
petitioner is entitled to compensation unless respondent can put forth preponderant evidence
“that [B.F.’s] injury was in fact caused by factors unrelated to the vaccine.” Whitecotton v.
Sec’y of Health & Human Servs., 17 F.3d 374 (Fed. Cir. 1994), rev’d on other grounds sub
nom., Shalala v. Whitecotton, 514 U.S. 268 (1995); see also Walther v. Sec’y of Health &
Human Servs., 485 F.3d 1146, 1151 (Fed. Cir. 2007). As discussed above, the undersigned
found the RSV infection was not the sole cause of B.F.’s condition, and that B.F.’s DTaP
vaccination was a but-for cause as well as a substantial factor in bringing about her condition.
See Shyface, 165 F.3d at 1352-53. Thus, respondent did not prove by a preponderance of
evidence that B.F.’s injury is “due to factors unrelated to the administration of the vaccine.” §
300aa-13(a)(1)(B).
G. Significant Aggravation Claim
Because the undersigned finds petitioner provided preponderant evidence under Althen
that the DTaP vaccine B.F. received on March 12, 2014 caused her to develop complex febrile
seizures and epilepsy, petitioner is entitled to compensation. Thus, the undersigned does not
need to address whether petitioner is entitled to compensation under the claim that the MMR
vaccine administered on September 18, 2014 significantly aggravated B.F.’s condition since the
undersigned has already determined petitioner is entitled to compensation.
IV. CONCLUSION
For the reasons discussed above, the undersigned finds that petitioner has established by
preponderant evidence that she is entitled to compensation. A separate damages order will issue.
IT IS SO ORDERED.
s/Nora Beth Dorsey
Nora Beth Dorsey
Special Master
24

================================================================================
DOCUMENT 2: USCOURTS-cofc-1_15-vv-01470-3
Date issued/filed: 2024-02-23
Pages: 22
Docket text: PUBLIC DECISION (Originally filed: 1/29/2024) regarding 252 DECISION Proffer. Signed by Special Master Nora Beth Dorsey. (kis) Service on parties made.
--------------------------------------------------------------------------------
Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 1 of 22
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
Filed: January 29, 2024
* * * * * * * * * * * * * * * *
ANDREA FULLER, on behalf of her * UNPUBLISHED
Minor Child, B.F., *
*
Petitioner, * No. 15-1470V
*
v. * Special Master Dorsey
*
SECRETARY OF HEALTH * Damages Award; Diphtheria-Tetanus-
AND HUMAN SERVICES, * Acellular Pertussis (“DTaP”) Vaccine;
* Measles Mumps Rubella (“MMR”) Vaccine;
Respondent. * Febrile Seizures; Epilepsy.
*
* * * * * * * * * * * * * * * *
Curtis R. Webb, Monmouth, OR, for Petitioner.
Mary Eileen Holmes, U.S. Department of Justice, Washington, DC, for Respondent.
DECISION AWARDING DAMAGES BASED ON PROFFER1
On December 4, 2015, Andrea Fuller (“Petitioner”), on behalf of her minor child, B.F.,
filed a petition for compensation under the National Vaccine Injury Compensation Program
(“Vaccine Act” or “the Program”), 42 U.S.C. § 300aa-10 et seq. (2018).2 Petitioner alleged that
as a result of receiving a diphtheria-tetanus-acellular-pertussis (“DTaP”) vaccine on March 12,
2014, B.F. suffered from complex febrile seizures and developed epilepsy, and a measles mumps
rubella (“MMR”) vaccine B.F. received on September 18, 2014 significantly aggravated B.F.’s
1 Because this Decision contains a reasoned explanation for the action in this case, the
undersigned is required to post it on the United States Court of Federal Claims’ website and/or at
https://www.govinfo.gov/app/collection/uscourts/national/cofc in accordance with the E-
Government Act of 2002. 44 U.S.C. § 3501 note (2018) (Federal Management and Promotion of
Electronic Government Services). This means the Decision will be available to anyone with
access to the Internet. In accordance with Vaccine Rule 18(b), Petitioner has 14 days to
identify and move to redact medical or other information, the disclosure of which would
constitute an unwarranted invasion of privacy. If, upon review, the undersigned agrees that the
identified material fits within this definition, the undersigned will redact such material from
public access.
2 The National Vaccine Injury Compensation Program is set forth in Part 2 of the National
Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755, codified as amended,
42 U.S.C. §§ 300aa-10 to -34 (2018). All citations in this Decision to individual sections of the
Vaccine Act are to 42 U.S.C. § 300aa.
1

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 2 of 22
condition. Amended Petition (“Am. Petition”) at 2 (ECF No. 132). On December 17, 2019, the
undersigned issued a ruling finding Petitioner entitled to compensation. Ruling on Entitlement
dated Dec. 17, 2019 (ECF No. 140).
On January 29, 2024, Respondent filed a Proffer on Award of Compensation (“Proffer”),
attached hereto as Appendix A. In the Proffer, Respondent represented that Petitioner agrees
with the proffered award. Proffer at 1-3. Based on the record as a whole, the undersigned finds
that Petitioner is entitled to an award as stated in the Proffer.
Pursuant to the terms stated in the attached Proffer, the undersigned awards Petitioner:
(1) A lump sum payment of $678,053.89, representing compensation for life care
expenses in the first year after judgment ($58,710.52), partial lost future
earnings ($404,343.37), and pain and suffering ($215,000.00), in the form of a
check payable to Petitioner, as guardian(s)/ conservator(s) of the estate of B.F.,
for the benefit of B.F.
(2) A lump sum payment of $10,272.66, representing compensation for past
unreimbursable expenses, in the form of a check payable to Petitioner, Andrea
Fuller.
(3) An amount sufficient to purchase the annuity contract, subject to the conditions
described in Section II.C., that will provide payments for the life care items
contained in the life care plan, as illustrated by the chart at Tab A attached to
the Proffer, paid to the life insurance company from which the annuity will be
purchased.
Proffer at 3-4.
In the absence of a motion for review filed pursuant to RCFC Appendix B, the Clerk of
the Court SHALL ENTER JUDGMENT herewith.3
IT IS SO ORDERED.
s/Nora Beth Dorsey
Nora Beth Dorsey
Special Master
3 Pursuant to Vaccine Rule 11(a), entry of judgment is expedited by the parties’ joint filing of
notice renouncing the right to seek review.
2

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 3 of 22
IN THE UNITED STATES COURT OF FEDERAL CLAIMS
OFFICE OF SPECIAL MASTERS
__________________________________________
)
ANDREA FULLER, on behalf of her )
Minor Child, B.F., )
Petitioner, )
)
v. ) No. 15-1470V
) Special Master Dorsey
SECRETARY OF THE DEPARTMENT OF ) ECF
HEALTH AND HUMAN SERVICES, )
)
Respondent. )
__________________________________________)
RESPONDENT'S PROFFER ON AWARD OF COMPENSATION
On December 4, 2015, Andrea Fuller (“petitioner”), on behalf of her minor child, B.F.,
filed a petition for compensation under the National Childhood Vaccine Injury Act of 1986, 42
U.S.C. §§ 300aa-1 to -34 (“Vaccine Act” or “Act”), alleging that as a result of receiving a
diphtheria-tetanus-acellular-pertussis (“DTaP”) vaccine on March 12, 2014, B.F. suffered from
complex febrile seizures and developed epilepsy, and further alleging that a measles mumps
rubella (“MMR”) vaccine B.F. received on September 18, 2014 significantly aggravated B.F.’s
condition. Amended Petition at 2 (ECF No. 132). On December 17, 2019, Special Master
Dorsey issued a Ruling on Entitlement in favor of petitioner. ECF No. 142. Respondent now
proffers the following regarding the amount of compensation to be awarded.1
1 The parties have no objection to the amount of the proffered award of damages. However,
respondent reserves his right, pursuant to 42 U.S.C. § 300aa-12(f), to seek review of the Special
Master’s December 17, 2019, Ruling on Entitlement, finding petitioner entitled to an award
under the Vaccine Act. This right accrues following the issuance of the damages decision.
-1-

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 4 of 22
I. Items of Compensation
A. Life Care Items
Respondent engaged life care planner M. Virginia Walton, M.S.N., RN, FNP, CNLCP,
and petitioner engaged Liz Kattman, M.S. and Helen Woodard, M.A., of ReEntry Rehabilitation
Services, Inc., to provide an estimation of B.F.’s future vaccine-injury related needs. For the
purposes of this proffer, the term “vaccine related” is as described in the Special Master’s
December 17, 2019 Ruling on Entitlement. All items of compensation identified in the life care
plan are supported by the evidence and are illustrated by the chart entitled Appendix A: Items of
Compensation for B.F., attached hereto as Tab A.2 Petitioner agrees.
B. Partial Lost Future Earnings
The parties agree that based upon the evidence of record, B.F. is not likely to be fully
employed in the future. Therefore, respondent proffers that B.F. should be awarded partial lost
future earnings as provided under the Vaccine Act, 42 U.S.C. § 300aa-15(a)(3)(B). Respondent
proffers that the appropriate award for B.F.'s partial lost future earnings is $404,343.37.
Petitioner agrees.
C. Pain and Suffering
Respondent proffers that B.F. should be awarded $215,000.00 in actual pain and
suffering. See 42 U.S.C. § 300aa-15(a)(4). Petitioner agrees.
2 The chart at Tab A illustrates the annual benefits provided by the life care plan. The annual
benefit years run from the date of judgment up to the first anniversary of the date of judgment,
and every year thereafter up to the anniversary of the date of judgment.
-2-

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 5 of 22
D. Past Unreimbursable Expenses
Evidence supplied by petitioner documents her expenditure of past unreimbursable
expenses related to B.F.’s vaccine-related injury. Respondent proffers that petitioner should be
awarded past unreimbursable expenses in the amount of $10,272.66. Petitioner agrees.
II. Form of the Award
The parties recommend that the compensation provided to B.F. should be made through a
combination of lump sum payments and future annuity payments as described below, and request
that the Special Master's decision and the Court's judgment award the following:3
A. A lump sum payment of $678,053.89, representing compensation for life care
expenses in the first year after judgment ($58,710.52), partial lost future earnings ($404,343.37),
and pain and suffering ($215,000.00), in the form of a check payable to petitioner, as
guardian(s)/ conservator(s) of the estate of B.F., for the benefit of B.F. No payments shall be
made until petitioner provides respondent with documentation establishing that she has been
appointed as the guardian(s)/conservator(s) of B.F.’s estate. If petitioner is not authorized by a
court of competent jurisdiction to serve as guardian(s)/conservator(s) of the estate of B.F., any
such payment shall be made to the party or parties appointed by a court of competent jurisdiction
to serve as guardian(s)/conservator(s) of the estate of B.F. upon submission of written
documentation of such appointment to the Secretary.
B. A lump sum payment of $10,272.66, representing compensation for past
unreimbursable expenses, in the form of a check payable to petitioner, Andrea Fuller.
3 Should B.F. die prior to entry of judgment, the parties reserve the right to move the Court for
appropriate relief. In particular, respondent would oppose any award for future medical
expenses, lost future earnings, and future pain and suffering.
-3-

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 6 of 22
C. An amount sufficient to purchase the annuity contract,4 subject to the conditions
described below, that will provide payments for the life care items contained in the life care plan,
as illustrated by the chart at Tab A attached hereto, paid to the life insurance company5 from
which the annuity will be purchased.6 Compensation for Year Two (beginning on the first
anniversary of the date of judgment) and all subsequent years shall be provided through
respondent's purchase of an annuity, which annuity shall make payments directly to petitioner
only so long as B.F. is alive at the time a particular payment is due. At the Secretary's sole
discretion, the periodic payments may be provided to petitioner in monthly, quarterly, annual or
other installments. The "annual amounts" set forth in the chart at Tab A describe only the total
yearly sum to be paid to petitioner and do not require that the payment be made in one annual
installment.
4 In respondent’s discretion, respondent may purchase one or more annuity contracts from one
or more life insurance companies.
5 The Life Insurance Company must have a minimum of $250,000,000 capital and surplus,
exclusive of any mandatory security valuation reserve. The Life Insurance Company must have
one of the following ratings from two of the following rating organizations:
a. A. M. Best Company: A++, A+, A+g, A+p, A+r, or A+s;
b. Moody's Investor Service Claims Paying Rating: Aa3, Aa2, Aa1, or Aaa;
c. Standard and Poor's Corporation Insurer Claims-Paying Ability Rating: AA-,
AA, AA+, or AAA;
d. Fitch Credit Rating Company, Insurance Company Claims Paying Ability
Rating: AA-, AA, AA+, or AAA.
6 Petitioner authorizes the disclosure of certain documents filed by the petitioner in this case
consistent with the Privacy Act and the routine uses described in the National Vaccine Injury
Compensation Program System of Records, No. 09-15-0056.
-4-

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 7 of 22
1. Growth Rate
Respondent proffers that a four percent (4%) growth rate should be applied to all non-
medical life care items, and a five percent (5%) growth rate should be applied to all medical life
care items. Thus, the benefits illustrated in the chart at Tab A that are to be paid through annuity
payments should grow as follows: four percent (4%) compounded annually from the date of
judgment for non-medical items, and five percent (5%) compounded annually from the date of
judgment for medical items. Petitioner agrees.
2. Life-Contingent Annuity
The petitioner will continue to receive the annuity payments from the Life Insurance
Company only so long as B.F. is alive at the time that a particular payment is due. Written
notice shall be provided to the Secretary of Health and Human Services and the Life Insurance
Company within twenty (20) days of B.F.’s death.
3. Guardianship
No payments shall be made until petitioner provides respondent with documentation
establishing that she has been appointed as the guardian(s)/conservator(s) of B.F.’s estate. If
petitioner is not authorized by a court of competent jurisdiction to serve as guardian(s)/
conservator(s) of the estate of B.F., any such payment shall be made to the party or parties
appointed by a court of competent jurisdiction to serve as guardian(s)/conservator(s) of the estate
of B.F. upon submission of written documentation of such appointment to the Secretary.
-5-

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 8 of 22
III. Summary of Recommended Payments Following Judgment
A. Lump Sum paid to the court-appointed guardian(s)/
conservator(s) of the estate of B.F. for the benefit of B.F.: $678,053.89
B. Past unreimbursable expenses payable to petitioner: $ 10,272.66
C. An amount sufficient to purchase the annuity contract described
above in section II. C.
Respectfully submitted,
BRIAN M. BOYNTON
Principal Deputy Assistant Attorney General
C. SALVATORE D’ALESSIO
Director
Torts Branch, Civil Division
HEATHER L. PEARLMAN
Deputy Director
Torts Branch, Civil Division
DARRYL R. WISHARD
Assistant Director
Torts Branch, Civil Division
/s/Mary E. Holmes
MARY E. HOLMES
Trial Attorney
Torts Branch, Civil Division
U. S. Department of Justice
P.O. Box l46, Benjamin Franklin Station
Washington, D.C. 20044-0146
Direct dial: (202) 616-5022
Mary.E.Holmes@usdoj.gov
Dated: January 29, 2024
-6-

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 9 of 22
Appendix A: Items of Compensation for B. F. Page 1 of 14
Lump Sum
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8
2024 2025 2026 2027 2028 2029 2030 2031
BlueCross Deductible/
Maximum out of Pocket 5% 2,500.00 2,500.00 500.00 500.00 500.00 500.00 500.00 500.00
ACA Premium 5% M
ACA Deductible 5%
Medicare Part B Deductible 5%
Medigap 5% M
Medicare Part D 5% M
Prmimary Care Physician 5% * 62.50 62.50 62.50 62.50 62.50 62.50
Neurologist 5% * 75.00 75.00 75.00 75.00 75.00 75.00
Psychiatry 5% * 100.00 100.00 100.00 100.00 100.00 100.00
Depakote 5% * 96.00 96.00 96.00 96.00 96.00 96.00
Diastat 5% * 159.40 159.40 159.40 159.40 159.40 159.40
Clonazepam 5% * 8.00 8.00 8.00 8.00 8.00 8.00
Luna OTC 4% 127.00 127.00 127.00 127.00 127.00 127.00 127.00 127.00
Lab Testing Draw Fee 5% * 14.40 14.40 14.40 14.40 14.40 14.40
Depakote Level 5% * 24.60 24.60 24.60 24.60 24.60 24.60
CBC w/ Differential 5% * 13.80 13.80 13.80 13.80 13.80 13.80
CMP 5% * 86.40 86.40 86.40 86.40 86.40 86.40
EEG Sleep Deprived 5% * 107.50 107.50 107.50 107.50 107.50 107.50
EEG 5% * 466.00
Respite Care 4% M 19,440.00 19,440.00 19,440.00 19,440.00 19,440.00 19,440.00 19,440.00
Aide Level Care 4% M 12,090.00 12,090.00 12,090.00 12,090.00 12,090.00 12,090.00 12,090.00 22,568.00
Assistance for Transportation 4% 360.00
Life Coaching 4% M 6,600.00 6,600.00 6,600.00 13,200.00 13,200.00
Cognitive Behavioral Therapy 4% *
Psychological Counseling 4% * 900.00 900.00 900.00 900.00 600.00 600.00
Neuropsych Evaluation 4% * 2,050.00
Case Management 4% M 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00
Speech Therapy Evaluations &
Speech Therapy 4% * M 18,000.00 12,240.00

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 10 of 22
Appendix A: Items of Compensation for B. F. Page 2 of 14
Lump Sum
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8
2024 2025 2026 2027 2028 2029 2030 2031
Tutoring 4% M 2,736.00 2,736.00 2,736.00 2,736.00 2,736.00 2,736.00 2,736.00 2,736.00
Voc Rehab Assess 4% 2,160.00
Heavy Housekeeping 4% M
Seizure Monitoring Watch 4% 249.00 83.00 83.00 83.00 83.00 83.00 83.00 83.00
Seizure Monitoring Watch
Monitoring 4% 240.00 240.00 240.00 240.00 240.00 240.00 240.00 240.00
Video Monitoring 4% 530.00 530.00
Cooling Towels/Blankets/Fan 4% 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00
Pill Box 4% 10.00 3.33 3.33 3.33 3.33 3.33 3.33 3.33
Medical Mileage 4% 146.52 146.52 146.52 146.52 146.52 146.52 146.52 146.52
Partial Lost Future Earnings 404,343.37
Pain and Suffering 215,000.00
Past Unreimbursable Expenses 10,272.66
Annual Totals 688,326.55 52,247.85 39,655.45 48,305.45 46,721.45 48,945.45 52,555.45 43,953.45
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of B.F., for the benefit of B.F., for partial lost future earnings ($404,343.37),
pain and suffering ($215,000.00), and Yr 1 life care expenses ($58,710.52): $678,053.89.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioner, Andrea Fuller,
for past un-reimbursable expenses: $10,272.66.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Annual amounts shall increase at the rates indicated in column "G.R." above, compounded annually from the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 11 of 22
Appendix A: Items of Compensation for B. F. Page 3 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Year 16
2032 2033 2034 2035 2036 2037 2038 2039
BlueCross Deductible/
Maximum out of Pocket 5% 500.00 500.00 500.00 500.00 500.00 500.00 500.00
ACA Premium 5% M 4,019.64
ACA Deductible 5% 600.00
Medicare Part B Deductible 5%
Medigap 5% M
Medicare Part D 5% M
Prmimary Care Physician 5% * 62.50 62.50 62.50 62.50 62.50 62.50 62.50 37.50
Neurologist 5% * 25.00 25.00 25.00 25.00 25.00 25.00 25.00 40.00
Psychiatry 5% * 100.00 100.00 100.00 100.00 100.00 100.00 100.00 160.00
Depakote 5% * 96.00 96.00 96.00 96.00 96.00 96.00 96.00 420.00
Diastat 5% * 159.40 159.40 159.40 159.40 159.40 159.40 159.40 100.00
Clonazepam 5% * 8.00 8.00 8.00 8.00 8.00 8.00 8.00 10.00
Luna OTC 4% 127.00 127.00 127.00 127.00 127.00 127.00 127.00 127.00
Lab Testing Draw Fee 5% * 14.40 14.40 14.40 14.40 14.40 14.40 14.40 20.00
Depakote Level 5% * 24.60 24.60 24.60 24.60 24.60 24.60 24.60 20.00
CBC w/ Differential 5% * 13.80 13.80 13.80 13.80 13.80 13.80 20.00
CMP 5% * 86.40 86.40 86.40 86.40 86.40 86.40 86.40 20.00
EEG Sleep Deprived 5% * 107.50 107.50 107.50 107.50 107.50 107.50 350.00
EEG 5% *
Respite Care 4% M
Aide Level Care 4% M 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00
Assistance for Transportation 4% 360.00 360.00 360.00 360.00 360.00 360.00 360.00 360.00
Life Coaching 4% M 13,200.00 13,200.00 13,200.00 13,200.00 13,200.00 6,600.00 6,600.00 3,300.00
Cognitive Behavioral Therapy 4% *
Psychological Counseling 4% * 600.00 600.00 600.00 600.00 600.00 600.00 600.00 180.00
Neuropsych Evaluation 4% *
Case Management 4% M 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00
Speech Therapy Evaluations &
Speech Therapy 4% * M

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 12 of 22
Appendix A: Items of Compensation for B. F. Page 4 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Year 16
2032 2033 2034 2035 2036 2037 2038 2039
Tutoring 4% M 2,736.00 2,736.00
Voc Rehab Assess 4% 432.00 432.00 432.00 432.00 432.00 432.00 432.00
Heavy Housekeeping 4% M 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00
Seizure Monitoring Watch 4% 83.00 83.00 83.00 83.00 83.00 83.00 83.00 83.00
Seizure Monitoring Watch
Monitoring 4% 240.00 240.00 240.00 240.00 240.00 240.00 240.00 240.00
Video Monitoring 4%
Cooling Towels/Blankets/Fan 4% 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00
Pill Box 4% 3.33 3.33 3.33 3.33 3.33 3.33 3.33 3.33
Medical Mileage 4% 48.84 48.84 48.84 48.84 48.84 48.84 48.84 48.84
Partial Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 44,885.77 45,317.77 42,581.77 42,581.77 42,581.77 35,981.77 35,860.47 36,881.31
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of B.F., for the benefit of B.F., for partial lost future earnings ($404,343.37),
pain and suffering ($215,000.00), and Yr 1 life care expenses ($58,710.52): $678,053.89.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioner, Andrea Fuller,
for past un-reimbursable expenses: $10,272.66.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Annual amounts shall increase at the rates indicated in column "G.R." above, compounded annually from the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 13 of 22
Appendix A: Items of Compensation for B. F. Page 5 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 17 Year 18 Year 19 Year 20 Year 21 Year 22 Year 23 Year 24
2040 2041 2042 2043 2044 2045 2046 2047
BlueCross Deductible/
Maximum out of Pocket 5%
ACA Premium 5% M 4,113.84 4,266.96 4,392.48 4,455.36 4,549.56 4,643.76 4,702.68 4,765.44
ACA Deductible 5% 600.00 600.00 600.00 600.00 600.00 600.00 600.00 600.00
Medicare Part B Deductible 5%
Medigap 5% M
Medicare Part D 5% M
Prmimary Care Physician 5% * 37.50 37.50 37.50 37.50 37.50 37.50 37.50 37.50
Neurologist 5% * 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00
Psychiatry 5% * 160.00 160.00 160.00 160.00 160.00 160.00 160.00 160.00
Depakote 5% * 420.00 420.00 420.00 420.00 420.00 420.00 420.00 420.00
Diastat 5% * 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Clonazepam 5% * 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00
Luna OTC 4% 127.00 127.00 127.00 127.00 127.00 127.00 127.00 127.00
Lab Testing Draw Fee 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
Depakote Level 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
CBC w/ Differential 5% * 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00
CMP 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
EEG Sleep Deprived 5% * 175.00 175.00 175.00 175.00 175.00 175.00 175.00 175.00
EEG 5% *
Respite Care 4% M
Aide Level Care 4% M 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00
Assistance for Transportation 4% 360.00 360.00 360.00 360.00 360.00 360.00 360.00 360.00
Life Coaching 4% M 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00
Cognitive Behavioral Therapy 4% *
Psychological Counseling 4% * 180.00 180.00 180.00 180.00 180.00 180.00 180.00 180.00
Neuropsych Evaluation 4% *
Case Management 4% M 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00
Speech Therapy Evaluations &
Speech Therapy 4% * M

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 14 of 22
Appendix A: Items of Compensation for B. F. Page 6 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 17 Year 18 Year 19 Year 20 Year 21 Year 22 Year 23 Year 24
2040 2041 2042 2043 2044 2045 2046 2047
Tutoring 4% M
Voc Rehab Assess 4% 432.00 432.00 432.00 432.00 432.00 432.00 432.00 432.00
Heavy Housekeeping 4% M 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00
Seizure Monitoring Watch 4% 83.00 83.00 83.00 83.00 83.00 83.00 83.00 83.00
Seizure Monitoring Watch
Monitoring 4% 240.00 240.00 240.00 240.00 240.00 240.00 240.00 240.00
Video Monitoring 4%
Cooling Towels/Blankets/Fan 4% 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00
Pill Box 4% 3.33 3.33 3.33 3.33 3.33 3.33 3.33 3.33
Medical Mileage 4% 48.84 48.84 48.84 48.84 48.84 48.84 48.84 48.84
Partial Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 36,790.51 36,943.63 37,069.15 37,132.03 37,226.23 37,320.43 37,379.35 37,442.11
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of B.F., for the benefit of B.F., for partial lost future earnings ($404,343.37),
pain and suffering ($215,000.00), and Yr 1 life care expenses ($58,710.52): $678,053.89.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioner, Andrea Fuller,
for past un-reimbursable expenses: $10,272.66.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Annual amounts shall increase at the rates indicated in column "G.R." above, compounded annually from the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 15 of 22
Appendix A: Items of Compensation for B. F. Page 7 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 25 Year 26 Year 27 Year 28 Year 29 Year 30 Year 31 Year 32
2048 2049 2050 2051 2052 2053 2054 2055
BlueCross Deductible/
Maximum out of Pocket 5%
ACA Premium 5% M 4,796.88 4,828.20 4,859.64 4,891.08 4,953.84 5,016.72 5,110.92 5,201.16
ACA Deductible 5% 600.00 600.00 600.00 600.00 600.00 600.00 600.00 600.00
Medicare Part B Deductible 5%
Medigap 5% M
Medicare Part D 5% M
Prmimary Care Physician 5% * 37.50 37.50 37.50 37.50 37.50 37.50 37.50 37.50
Neurologist 5% * 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00
Psychiatry 5% * 160.00 160.00 160.00 160.00 160.00 160.00 160.00 160.00
Depakote 5% * 420.00 420.00 420.00 420.00 420.00 420.00 420.00 420.00
Diastat 5% * 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Clonazepam 5% * 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00
Luna OTC 4% 127.00 127.00 127.00 127.00 127.00 127.00 127.00 127.00
Lab Testing Draw Fee 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
Depakote Level 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
CBC w/ Differential 5% * 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00
CMP 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
EEG Sleep Deprived 5% * 175.00 175.00 175.00 175.00 175.00 175.00 175.00 175.00
EEG 5% *
Respite Care 4% M
Aide Level Care 4% M 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00
Assistance for Transportation 4% 360.00 360.00 360.00 360.00 360.00 360.00 360.00 360.00
Life Coaching 4% M 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00
Cognitive Behavioral Therapy 4% *
Psychological Counseling 4% * 180.00 75.00 75.00 75.00 75.00 75.00 75.00 75.00
Neuropsych Evaluation 4% *
Case Management 4% M 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00
Speech Therapy Evaluations &
Speech Therapy 4% * M

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 16 of 22
Appendix A: Items of Compensation for B. F. Page 8 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 25 Year 26 Year 27 Year 28 Year 29 Year 30 Year 31 Year 32
2048 2049 2050 2051 2052 2053 2054 2055
Tutoring 4% M
Voc Rehab Assess 4% 432.00 432.00 432.00 432.00 432.00 432.00 432.00 432.00
Heavy Housekeeping 4% M 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00
Seizure Monitoring Watch 4% 83.00 83.00 83.00 83.00 83.00 83.00 83.00 83.00
Seizure Monitoring Watch
Monitoring 4% 240.00 240.00 240.00 240.00 240.00 240.00 240.00 240.00
Video Monitoring 4%
Cooling Towels/Blankets/Fan 4% 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00
Pill Box 4% 3.33 3.33 3.33 3.33 3.33 3.33 3.33 3.33
Medical Mileage 4% 48.84 48.84 48.84 48.84 48.84 48.84 48.84 48.84
Partial Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 37,473.55 37,399.87 37,431.31 37,462.75 37,525.51 37,588.39 37,682.59 37,772.83
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of B.F., for the benefit of B.F., for partial lost future earnings ($404,343.37),
pain and suffering ($215,000.00), and Yr 1 life care expenses ($58,710.52): $678,053.89.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioner, Andrea Fuller,
for past un-reimbursable expenses: $10,272.66.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Annual amounts shall increase at the rates indicated in column "G.R." above, compounded annually from the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 17 of 22
Appendix A: Items of Compensation for B. F. Page 9 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 33 Year 34 Year 35 Year 36 Year 37 Year 38 Year 39 Year 40
2056 2057 2058 2059 2060 2061 2062 2063
BlueCross Deductible/
Maximum out of Pocket 5%
ACA Premium 5% M 5,326.80 5,483.76 5,668.32 5,888.16 6,135.36 6,418.08 6,696.72 7,010.76
ACA Deductible 5% 600.00 600.00 600.00 600.00 600.00 600.00 600.00 600.00
Medicare Part B Deductible 5%
Medigap 5% M
Medicare Part D 5% M
Prmimary Care Physician 5% * 37.50 37.50 37.50 37.50 37.50 37.50 37.50 37.50
Neurologist 5% * 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00
Psychiatry 5% * 160.00 160.00 160.00 160.00 160.00 160.00 160.00 160.00
Depakote 5% * 420.00 420.00 420.00 420.00 420.00 420.00 420.00 420.00
Diastat 5% * 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Clonazepam 5% * 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00
Luna OTC 4% 127.00 127.00 127.00 127.00 127.00 127.00 127.00 127.00
Lab Testing Draw Fee 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
Depakote Level 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
CBC w/ Differential 5% * 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00
CMP 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
EEG Sleep Deprived 5% * 175.00 175.00 175.00 175.00 175.00 175.00 175.00 175.00
EEG 5% *
Respite Care 4% M
Aide Level Care 4% M 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00
Assistance for Transportation 4% 360.00 360.00 360.00 360.00 360.00 360.00 360.00 360.00
Life Coaching 4% M 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00
Cognitive Behavioral Therapy 4% *
Psychological Counseling 4% * 75.00 75.00 75.00 75.00 75.00 75.00 75.00 75.00
Neuropsych Evaluation 4% *
Case Management 4% M 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00
Speech Therapy Evaluations &
Speech Therapy 4% * M

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 18 of 22
Appendix A: Items of Compensation for B. F. Page 10 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 33 Year 34 Year 35 Year 36 Year 37 Year 38 Year 39 Year 40
2056 2057 2058 2059 2060 2061 2062 2063
Tutoring 4% M
Voc Rehab Assess 4% 432.00 432.00 432.00 432.00 432.00 432.00 432.00 432.00
Heavy Housekeeping 4% M 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00
Seizure Monitoring Watch 4% 83.00 83.00 83.00 83.00 83.00 83.00 83.00 83.00
Seizure Monitoring Watch
Monitoring 4% 240.00 240.00 240.00 240.00 240.00 240.00 240.00 240.00
Video Monitoring 4%
Cooling Towels/Blankets/Fan 4% 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00
Pill Box 4% 3.33 3.33 3.33 3.33 3.33 3.33 3.33 3.33
Medical Mileage 4% 48.84 48.84 48.84 48.84 48.84 48.84 48.84 48.84
Partial Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 37,898.47 38,055.43 38,239.99 38,459.83 38,707.03 38,989.75 39,268.39 39,582.43
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of B.F., for the benefit of B.F., for partial lost future earnings ($404,343.37),
pain and suffering ($215,000.00), and Yr 1 life care expenses ($58,710.52): $678,053.89.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioner, Andrea Fuller,
for past un-reimbursable expenses: $10,272.66.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Annual amounts shall increase at the rates indicated in column "G.R." above, compounded annually from the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 19 of 22
Appendix A: Items of Compensation for B. F. Page 11 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 41 Year 42 Year 43 Year 44 Year 45 Year 46 Year 47 Year 48
2064 2065 2066 2067 2068 2069 2070 2071
BlueCross Deductible/
Maximum out of Pocket 5%
ACA Premium 5% M 7,320.84 7,662.36 8,007.84 8,380.80 8,753.64 9,158.04 9,566.28 10,002.00
ACA Deductible 5% 600.00 600.00 600.00 600.00 600.00 600.00 600.00 600.00
Medicare Part B Deductible 5%
Medigap 5% M
Medicare Part D 5% M
Prmimary Care Physician 5% * 37.50 37.50 37.50 37.50 37.50 37.50 37.50 37.50
Neurologist 5% * 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00
Psychiatry 5% * 160.00 160.00 160.00 160.00 160.00 160.00 160.00 160.00
Depakote 5% * 420.00 420.00 420.00 420.00 420.00 420.00 420.00 420.00
Diastat 5% * 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Clonazepam 5% * 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00
Luna OTC 4% 127.00 127.00 127.00 127.00 127.00 127.00 127.00 127.00
Lab Testing Draw Fee 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
Depakote Level 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
CBC w/ Differential 5% * 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00
CMP 5% * 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
EEG Sleep Deprived 5% * 175.00 175.00 175.00 175.00 175.00 175.00 175.00 175.00
EEG 5% *
Respite Care 4% M
Aide Level Care 4% M 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00
Assistance for Transportation 4% 360.00 360.00 360.00 360.00 360.00 360.00 360.00 360.00
Life Coaching 4% M 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00
Cognitive Behavioral Therapy 4% *
Psychological Counseling 4% * 75.00 75.00 75.00 75.00 75.00 75.00 75.00 75.00
Neuropsych Evaluation 4% *
Case Management 4% M 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00
Speech Therapy Evaluations &
Speech Therapy 4% * M

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 20 of 22
Appendix A: Items of Compensation for B. F. Page 12 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 41 Year 42 Year 43 Year 44 Year 45 Year 46 Year 47 Year 48
2064 2065 2066 2067 2068 2069 2070 2071
Tutoring 4% M
Voc Rehab Assess 4% 432.00 432.00 432.00 432.00 432.00 432.00 432.00 432.00
Heavy Housekeeping 4% M 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00
Seizure Monitoring Watch 4% 83.00 83.00 83.00 83.00 83.00 83.00 83.00 83.00
Seizure Monitoring Watch
Monitoring 4% 240.00 240.00 240.00 240.00 240.00 240.00 240.00 240.00
Video Monitoring 4%
Cooling Towels/Blankets/Fan 4% 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00
Pill Box 4% 3.33 3.33 3.33 3.33 3.33 3.33 3.33 3.33
Medical Mileage 4% 48.84 48.84 48.84 48.84 48.84 48.84 48.84 48.84
Partial Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 39,892.51 40,234.03 40,579.51 40,952.47 41,325.31 41,729.71 42,137.95 42,573.67
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of B.F., for the benefit of B.F., for partial lost future earnings ($404,343.37),
pain and suffering ($215,000.00), and Yr 1 life care expenses ($58,710.52): $678,053.89.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioner, Andrea Fuller,
for past un-reimbursable expenses: $10,272.66.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Annual amounts shall increase at the rates indicated in column "G.R." above, compounded annually from the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 21 of 22
Appendix A: Items of Compensation for B. F. Page 13 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 49 Year 50 Year 51 Year 52 Year 53 Year 54 Years 55-56 Years 57-Life
2072 2073 2074 2075 2076 2077 2078-2079 2080-Life
BlueCross Deductible/
Maximum out of Pocket 5%
ACA Premium 5% M 10,217.88 10,653.60 11,030.40 11,277.72 11,587.80 11,775.96
ACA Deductible 5% 600.00 600.00 600.00 600.00 600.00 600.00
Medicare Part B Deductible 5% 240.00 240.00
Medigap 5% M 2,412.00 2,412.00
Medicare Part D 5% M 1,715.16 1,715.16
Prmimary Care Physician 5% * 37.50 37.50 37.50 37.50 37.50 37.50
Neurologist 5% * 40.00 40.00 40.00 40.00 40.00 40.00
Psychiatry 5% * 160.00 160.00 160.00 160.00 160.00 160.00
Depakote 5% * 420.00 420.00 420.00 420.00 420.00 420.00
Diastat 5% * 100.00 100.00 100.00 100.00 100.00 100.00
Clonazepam 5% * 10.00 10.00 10.00 10.00 10.00 10.00
Luna OTC 4% 127.00 127.00 127.00 127.00 127.00 127.00 127.00 127.00
Lab Testing Draw Fee 5% * 20.00 20.00 20.00 20.00 20.00 20.00
Depakote Level 5% * 20.00 20.00 20.00 20.00 20.00 20.00
CBC w/ Differential 5% * 10.00 10.00 10.00 10.00 10.00 10.00
CMP 5% * 20.00 20.00 20.00 20.00 20.00 20.00
EEG Sleep Deprived 5% * 175.00 175.00 175.00 175.00 175.00 175.00
EEG 5% *
Respite Care 4% M
Aide Level Care 4% M 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00 22,568.00
Assistance for Transportation 4% 360.00 360.00 360.00 360.00 360.00 360.00 360.00 360.00
Life Coaching 4% M 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00 3,300.00
Cognitive Behavioral Therapy 4% *
Psychological Counseling 4% * 75.00 75.00 75.00 75.00 75.00 75.00
Neuropsych Evaluation 4% *
Case Management 4% M 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00 2,592.00
Speech Therapy Evaluations &
Speech Therapy 4% * M

Case 1:15-vv-01470-UNJ Document 253 Filed 02/23/24 Page 22 of 22
Appendix A: Items of Compensation for B. F. Page 14 of 14
ITEMS OF Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
COMPENSATION G.R. * M Year 49 Year 50 Year 51 Year 52 Year 53 Year 54 Years 55-56 Years 57-Life
2072 2073 2074 2075 2076 2077 2078-2079 2080-Life
Tutoring 4% M
Voc Rehab Assess 4% 432.00 432.00 432.00 432.00 432.00 432.00 432.00
Heavy Housekeeping 4% M 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00 1,080.00
Seizure Monitoring Watch 4% 83.00 83.00 83.00 83.00 83.00 83.00 83.00 83.00
Seizure Monitoring Watch
Monitoring 4% 240.00 240.00 240.00 240.00 240.00 240.00 240.00 240.00
Video Monitoring 4%
Cooling Towels/Blankets/Fan 4% 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00
Pill Box 4% 3.33 3.33 3.33 3.33 3.33 3.33 3.33 3.33
Medical Mileage 4% 48.84 48.84 48.84 48.84 48.84 48.84 48.84 48.84
Partial Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 42,789.55 43,225.27 43,602.07 43,849.39 44,159.47 44,347.63 35,251.33 34,819.33
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of B.F., for the benefit of B.F., for partial lost future earnings ($404,343.37),
pain and suffering ($215,000.00), and Yr 1 life care expenses ($58,710.52): $678,053.89.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioner, Andrea Fuller,
for past un-reimbursable expenses: $10,272.66.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Annual amounts shall increase at the rates indicated in column "G.R." above, compounded annually from the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.